[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 990
1. Nishimura Y, Watanabe J, Jobo T, Hattori M, Arai T, Kuramoto H: Cytologic scoring of endometrioid adenocarcinoma of the endometrium. Cancer; 2005 Feb 25;105(1):8-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic scoring of endometrioid adenocarcinoma of the endometrium.
  • BACKGROUND: Endometrial carcinoma is one of the most frequent malignancies in the female genital tract, and its incidence has been increasing in Japan.
  • The objective of this study was to evaluate the applicability and usefulness of cytologic scoring in assessing the morphologic differentiation of endometrioid adenocarcinomas of the endometrium using endometrial smears.
  • METHODS: Sixty-four endometrial cytologic samples of endometrioid adenocarcinomas of the endometrium were used in this study.
  • All patients underwent endometrial cytology before hysterectomy, and the diagnosis was confirmed by histologic examination of the extirpated uterus.
  • Each cytologic specimen was scored according to a scoring system established by the authors.
  • CONCLUSIONS: The cytologic scoring system studied for endometrioid adenocarcinoma was useful for predicting histologic grade and tumor malignant potential.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Cell Differentiation. Female. Genes, p53. Humans. Mutation. Neoplasm Metastasis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 American Cancer Society
  • (PMID = 15597380.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


2. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Carcinoembryonic Antigen / metabolism. Combined Modality Therapy. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Necrosis. Vulvar Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175478.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


3. Ikeda M, Kurose A, Takatori E, Sugiyama T, Traganos F, Darzynkiewicz Z, Sawai T: DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines. Int J Oncol; 2010 May;36(5):1081-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines.
  • Using multiparameter cytometry we explored the effects of doxorubicin (DOX), cisplatin (CDDP) and 5-fluorouracil (5-FU) on four types of endometrioid adenocarcinoma cell lines (HEC-1A, HEC-1B, Ishikawa, KLE) correlating the drug-induced increases in phosphorylated H2AX (gammaH2AX) with cell cycle phase, induction of apoptosis and induction of cell senescence, the latter detected by analysis of beta-galactosidase.
  • The data suggest that the treatment of endometrioid adenocarcinoma with these drugs may have to be customized to individual patients.

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] DNA Repair (Amst). 2009 Sep 2;8(9):1038-46 [19482564.001]
  • [Cites] Oral Oncol. 1998 May;34(3):198-203 [9692054.001]
  • [Cites] J Oral Pathol Med. 1998 Sep;27(8):367-75 [9736425.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):643-53 [10690550.001]
  • [Cites] Blood. 2000 Jul 1;96(1):307-13 [10891466.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):657-63 [11259608.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1862-8 [11280739.001]
  • [Cites] Arch Biochem Biophys. 2002 Jan 15;397(2):262-72 [11795881.001]
  • [Cites] Radiat Res. 2002 Oct;158(4):486-92 [12236816.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):457-63 [12580960.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62 [12679524.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4347-50 [12907603.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7265-79 [14576837.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Oct;30(11):1855-8 [14619538.001]
  • [Cites] Cytometry A. 2004 Apr;58(2):99-110 [15057963.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3902-8 [15459211.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Aug 30;123(1):291-8 [6477583.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):68-70 [2703169.001]
  • [Cites] Vet Pathol. 1998 Nov;35(6):461-78 [9823588.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):539-45 [10203588.001]
  • [Cites] J Cell Biochem. 1999 May 1;73(2):259-77 [10227389.001]
  • [Cites] J Cell Biol. 1999 Sep 6;146(5):905-16 [10477747.001]
  • [Cites] Cytometry A. 2005 Nov;68(1):1-9 [16184611.001]
  • [Cites] Cancer Biol Ther. 2006 Aug;5(8):959-64 [16760673.001]
  • [Cites] EMBO J. 2006 Dec 13;25(24):5775-82 [17124492.001]
  • [Cites] Cytometry A. 2007 Nov;71(11):905-14 [17879239.001]
  • [Cites] Yakugaku Zasshi. 2007 Nov;127(11):1837-42 [17978559.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):803-8 [18283299.001]
  • [Cites] Cytometry A. 2008 Jun;73(6):480-9 [18459160.001]
  • [Cites] J Biol Chem. 1998 Mar 6;273(10):5858-68 [9488723.001]
  • (PMID = 20372780.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA028704-30; United States / NCI NIH HHS / CA / R01 CA028704; United States / NCI NIH HHS / CA / R01 CA028704-30
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / H2AFX protein, human; 0 / Histones; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS247428; NLM/ PMC2972583
  •  go-up   go-down


Advertisement
4. Castillo-Sang M, Slam K, Gociman B, Durham SJ, Booth R: Endometrial adenocarcinoma metastatic to the right ventricle: a case report and review of the literature. Cardiovasc Pathol; 2009 May-Jun;18(3):178-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma metastatic to the right ventricle: a case report and review of the literature.
  • BACKGROUND: Endometrial adenocarcinoma of any histologic type rarely metastasizes to the heart.
  • METHODS AND RESULTS: A 62-year-old female was admitted for increasing shortness of breath over the previous month.
  • Her past medical history was significant for a resected Stage IC endometrial adenocarcinoma endometrioid type 15 months prior.
  • The tumor was found to be a poorly differentiated (Grade 3) endometrial adenocarcinoma invading over half the myometrium.
  • Subsequent endocardial biopsy showed a poorly differentiated, Grade 3, endometrial adenocarcinoma of endometrioid histologic type.
  • CONCLUSION: Management of metastatic adenocarcinoma to the heart is not well established due to the rarity of this lesion.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Heart Neoplasms / secondary
  • [MeSH-minor] Biopsy. Cell Differentiation. Echocardiography. Fatal Outcome. Female. Heart Ventricles / pathology. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402828.001).
  • [ISSN] 1879-1336
  • [Journal-full-title] Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
  • [ISO-abbreviation] Cardiovasc. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


5. Hirschowitz L, Sen C, Murdoch J: Primary endometrioid adenocarcinoma of the cervix with widespread squamous metaplasia--a potential diagnostic pitfall. Diagn Pathol; 2007;2:40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary endometrioid adenocarcinoma of the cervix with widespread squamous metaplasia--a potential diagnostic pitfall.
  • BACKGROUND: Uterine or endocervical biopsies that contain endometrioid adenocarcinoma with widespread squamous metaplasia are usually of endometrial origin.
  • The presence of squamous metaplasia is said to be helpful in distinguishing endocervical from endometrial adenocarcinomas in small biopsy samples.
  • Biopsy of a friable lesion in the proximal endocervical canal revealed an endocervical adenocarcinoma of endometrioid type with widespread squamous metaplasia.
  • The latter feature initially raised the possible diagnosis of a primary endometrial adenocarcinoma.
  • However, immunohistochemical marker studies indicated a diagnosis of primary endocervical adenocarcinoma of endometrioid type and this was confirmed at hysterectomy.
  • CONCLUSION: Squamous differentiation is not well documented in endocervical adenocarcinomas of endometrioid type and, when widespread, may represent a diagnostic pitfall for pathologists.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):360-7 [12352184.001]
  • [Cites] Histopathology. 2002 Sep;41(3):185-207 [12207781.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):1-3 [11781515.001]
  • [Cites] Mod Pathol. 1999 Dec;12(12):1137-42 [10619266.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):164-73 [12610091.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):8-15 [16462152.001]
  • [Cites] Am J Surg Pathol. 1980 Oct;4(5):481-9 [7435776.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1291-9 [11002225.001]
  • [Cites] Diagn Pathol. 2007;2:26 [17645802.001]
  • [Cites] Diagn Pathol. 2006;1:30 [16981999.001]
  • [Cites] Cancer. 1991 Nov 15;68(10):2293-302 [1913465.001]
  • (PMID = 17961245.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2116996
  •  go-up   go-down


6. Shaco-Levy R, Piura B: Endometrioid endometrial adenocarcinoma recurring as carcinosarcoma. J Obstet Gynaecol Res; 2008 Apr;34(2):279-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid endometrial adenocarcinoma recurring as carcinosarcoma.
  • Müllerian carcinosarcoma is currently regarded as a metaplastic (sarcomatous) carcinoma.
  • Only five cases of pure ovarian adenocarcinoma recurring as carcinosarcoma have been documented in the literature.
  • There are no documented cases of endometrial adenocarcinoma recurring as metaplastic carcinoma.
  • We report of a case of endometrial adenocarcinoma, endometrioid type, recurring as metaplastic carcinoma showing sarcomatous differentiation.
  • The tumor evolution in this case supports the prevailing opinion that Müllerian carcinosarcomas are derived from carcinomas and represent tumor progression.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinosarcoma / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18412798.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Kozawa E, Matsuo Y, Hasegawa K, Fujiwara K, Sakurai T, Kimura F: Spontaneously ruptured endometrioma associated with endometrioid adenocarcinoma: MR findings. Magn Reson Med Sci; 2010;9(4):233-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneously ruptured endometrioma associated with endometrioid adenocarcinoma: MR findings.
  • Histologic examination following adnexectomy revealed a ruptured endometrioma associated with endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Diagnosis, Differential. Female. Humans. Rupture, Spontaneous

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187693.001).
  • [ISSN] 1880-2206
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Liu X, Xia W, Dai YM, Shao NS, Zhang WY: [Expression of microRNAs in endometrioid adenocarcinoma]. Zhonghua Yi Xue Za Zhi; 2009 May 19;89(19):1365-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of microRNAs in endometrioid adenocarcinoma].
  • OBJECTIVE: To analyze miRNA expression profile of endometrioid adenocarcinoma.
  • The microarray detection system was employed to analyze whether there was difference in microRNA expression between cancer tissue and park cancer tissue.
  • CONCLUSION: MiRNA may play important roles in tumorigenesis of endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. MicroRNAs / genetics
  • [MeSH-minor] Exosomes. Female. Gene Expression Profiling. Humans. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615196.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


9. Wu W, Lin Z, Zhuang Z, Liang X: Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):50-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of mammalian microRNAs in endometrioid adenocarcinoma.
  • The specific expression profiles of miRNAs have been found in many human cancers, but there are few studies on endometrioid adenocarcinoma.
  • We found the miRNA expression profile in 10 pairs of endometrioid adenocarcinoma and adjacent nontumorous endometrium using human miRNA microarray.
  • Seventeen miRNAs exhibited higher expression and six miRNAs exhibited lower expression in endometrioid adenocarcinoma samples than those in the nontumorous samples in the microarray.
  • Of those, the miR-205, miR-449, and miR-429 were greatly enriched; in contrast the miR-204, miR-99b, and miR-193b were greatly downregulated in adenocarcinoma tissues.
  • This information may provide the candidate miRNA genome for further confirming the role of miRNAs in carcinogenesis of endometrioid adenocarcinoma and potentially serving as a diagnostic or therapeutic tool in endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Endometrial Neoplasms / genetics. Gene Expression Profiling. MicroRNAs / genetics
  • [MeSH-minor] Animals. False Positive Reactions. Female. Gene Expression Regulation, Neoplastic. Humans. Mammals / genetics. Mice. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077565.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


10. Wei S, Conner MG, Zhang K, Siegal GP, Novak L: Juxtatumoral stromal reactions in uterine endometrioid adenocarcinoma and their prognostic significance. Int J Gynecol Pathol; 2010 Nov;29(6):562-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juxtatumoral stromal reactions in uterine endometrioid adenocarcinoma and their prognostic significance.
  • Uterine endometrioid adenocarcinoma is the most common invasive tumor of the female genital tract in the United States.
  • We thus examined a total of 103 consecutive cases of invasive uterine endometrioid adenocarcinoma in an attempt to determine if an association exists between the stromal reactions and other well-defined histologic and clinical prognostic factors.
  • We found that the presence of a desmoplastic reaction was associated with a higher International Federation of Gynecology and Obstetrics (FIGO) grade (P<0.01) and lymphovascular invasion (LVI) (P<0.05), and advanced FIGO stage (stage IB vs. IC, P<0.01; stage I vs. II/III/IV, P<0.05).
  • Our findings revealed that a strong lymphocytic stromal response was predominantly found in the uterine endometrioid adenocarcinomas with early clinical stages.
  • The presence of a desmoplastic reaction in the stroma should prompt the pathologist to search for other histologically unfavorable prognostic indicators such as cervical involvement and nodal metastasis.
  • This is even more important in those cases where no staging procedure was performed and in cases where the tumor was an incidental finding.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Extracellular Matrix / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Inflammation / pathology. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881855.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Xiong Y, Xiong YY, Zhou YF: [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):594-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
  • OBJECTIVE: To explore the expression of beta-catenin, Glut-1, PTEN in uterine endometrioid adenocarcinoma and their roles in tumorigenesis.
  • Expressions of beta-catenin, Glut-1 and PTEN proteins were investigated by immunohistochemistry in 10 proliferative endometrium, 83 endometrial hyperplasia and 24 endometrioid adenocarcinoma. RESULTS:.
  • (1) 24 EIN (28.9%) lesions were reclassified among 83 previously diagnosed endometrial hyperplasia, of which, 16 of 24 EIN cases (66.7%) had a prior diagnosis of complex atypical hyperplasia.
  • The relation between EIN diagnosis and grade of atypical hyperplasia was not obvious (P > 0.05). (2) Normal (membranous) expression of beta-catenin was present in 10 cases of proliferative endometrium.
  • Abnormal (marked membranous/cytoplasmic, cytoplasmic and/or nuclear or negative) expression rates of beta-catenin in EIN lesions (50%, 12/24) and endometrioid adenocarcinoma (66.7%, 16/24) were significantly higher than that of benign hyperplasia (10.2%, 6/59) respectively (P < 0.01).
  • However, the difference was not significant between EIN lesions and endometrioid adenocarcinomas (P > 0.05). (3) Low level expressions of Glut-1 was present in proliferative endometrium and benign hyperplasia.
  • Overexpression of Glut-1 was present in 58.3% (14/24) of EIN and 70.8% (17/24) of endometrioid adenocarcinoma, respectively, and statistically not significant (P > 0.05). (4) Percentages of loss of PTEN expression showed no difference between EIN lesions (37.5%, 9/24) and proliferative endometrium (2/10), benign hyperplasia (28.8%, 17/59), endometrioid adenocarcinoma (62.5%, 15/24; P > 0.05).
  • However, loss of PTEN expression in endometrioid adenocarcinoma was significantly higher than those in proliferative endometrium and benign hyperplasia (P < 0.05).
  • CONCLUSIONS: Abnormal expression of beta-catenin and overexpression of Glut-1 may be the early events in tumorigenesis of endometrioid adenocarcinoma.
  • The expression of both markers may be useful in distinguishing a benign hyperplasia from EIN and endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Glucose Transporter Type 1 / metabolism. PTEN Phosphohydrolase / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Hyperplasia / pathology. Female. Humans. Immunohistochemistry. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079187.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / beta Catenin; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


12. Kuwabara Y, Susumu N, Banno K, Hirao T, Kawaguchi M, Yamagami W, Suzuki N, Aoki D, Nozawa S: Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan. Jpn J Clin Oncol; 2005 Jan;35(1):23-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan.
  • BACKGROUND: It has been reported that prognosis is less favorable in poorly (G3) differentiated endometrioid adenocarcinoma than in well (G1) or moderately (G2) differentiated endometrioid adenocarcinoma.
  • The goal of this study is therefore to analyze the prognosis of G3 endometrioid adenocarcinoma and various factors that may predict a favorable prognosis.
  • METHOD: This study included 699 Japanese cases of endometrioid adenocarcinoma at the International Federation of Gynaecology and Obstetrics (FIGO) surgical stages I-IV (including 74 G3 cases).
  • We investigated the G1-G3 survival rates of endometrioid adenocarcinoma cases and the G2 and G3 disease-free periods.
  • We also examined the clinicopathological characteristics of G3 endometrioid adenocarcinoma.
  • The absence of adnexal metastasis and low pre-surgery CA19-9 values may suggest a relatively favorable prognosis in G3 endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Cell Cycle. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / secondary. Prognosis. Survival Rate. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15681600.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Nabli H, Tuller E, Sharpe-Timms KL: Haptoglobin expression in endometrioid adenocarcinoma of the uterus. Reprod Sci; 2010 Jan;17(1):47-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haptoglobin expression in endometrioid adenocarcinoma of the uterus.
  • We have shown that Hp is produced by and localizes only in the stroma and not the epithelium of endometriotic lesions, which share many characteristics of carcinoma.
  • We hypothesized that characteristic patterns of Hp gene expression and protein localization in endometrioid adenocarcinoma of the uterus may provide insight into the clinical utility of Hp as a tumor marker or alternative therapeutic approach.
  • METHODS: Biopsies of endometrioid adenocarcinoma tumors of the uterus and their adjacent nonaffected endometrium were collected.
  • RESULTS: Haptoglobin mRNA levels were significantly greater (P < .005) in endometrioid adenocarcinoma and adjacent nonaffected endometrial tissues than normal endometrium.
  • Haptoglobin protein localized in both stromal and glandular epithelial cells of endometrioid adenocarcinoma and their adjacent nonaffected tissue but not in control endometrium.
  • CONCLUSIONS: Our results have identified, for the first time, unique patterns of Hp mRNA expression and protein localization in the stromal and glandular epithelial cells of endometrioid adenocarcinoma of the uterus.
  • We propose that this unique pattern of endometrioid adenocarcinoma Hp expression may be developed as a novel diagnostic marker.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Haptoglobins / metabolism
  • [MeSH-minor] Adult. Analysis of Variance. Epithelial Cells / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801537.001).
  • [ISSN] 1933-7205
  • [Journal-full-title] Reproductive sciences (Thousand Oaks, Calif.)
  • [ISO-abbreviation] Reprod Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Haptoglobins; 0 / RNA, Messenger
  •  go-up   go-down


14. Tominaga E, Tsuda H, Arao T, Nishimura S, Chiyoda T, Nomura H, Kataoka F, Susumu N, Aoki D, Nishio K: Use of amplification of the 8q24 and 20q11-13 loci to predict progression-free survival of advanced epithelial ovarian cancer patients receiving standard therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty three aEOC patients (stage IIc: 4, III: 19, IV: 10; serous adenocarcinoma: 21, endometrioid adenocarcinoma: 5, undifferentiated: 7) were included in this array study.
  • RESULTS: Class comparison analysis between groups of NED (no evidence of disease) and non-NED identified 46 genes that exhibited significant differences (p < 0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960791.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Nagao S, Oishi R, Iwasa N, Shimizu M, Hasegawa K, Goto T, Fujiwara K: A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16549

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma.
  • : e16549 Background: This is a feasibility study for a future trial to assess the feasibility of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin and IP paclitaxel (TCipTip therapy) in patients with epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.
  • METHODS: The patients eligible for this study had histologically confirmed, stage IC-IV epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.
  • The patients included 7 epithelial ovarian carcinoma (stage IC, 2; stage IIIC, 5), 2 stage IIIC primary peritoneal carcinoma, and 1 stage IIA fallopian tube carcinoma.
  • There were 7 serous adenocarcinoma, 2 endometrioid adenocarcinoma, 1 clear cell adenocarcinoma.
  • CONCLUSIONS: TCipTip therapy is feasible for patients with epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960819.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Espino-Strebel E, Luna JT: Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Ninety patients with endometrioid endometrial adenocarcinoma were included.
  • It was also significantly correlated with extrauterine disease (p = 0.01).
  • CONCLUSIONS: Preoperative serum CA125 has a significant correlation with deep myometrial invasion, adnexal metastasis, pelvic and para-aortic lymph node involvement, and extrauterine disease at a cutoff value of 55U/mL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960797.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lord SR, Vasudev N, Knight S, Speirs V, Hall G: Prognostic significance of immunohistochemical markers in endometrial cancer treated with chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: For a subset of patients with either endometrioid, serous or a mixed mullerian morphology treated with chemotherapy at our centre between 1996 and 2008 an immunohistochemical profile of 14 biomarkers was studied (ERα, Erβ1, Erβ2, PR, PRB, P53, Rb, E-cad, MDM2, MIB-1, E2F1, p16, p13, and p21).
  • The commonest histological subtypes were endometrioid adenocarcinoma (40%), serous carcinoma (24.1%) and mixed mullerian tumours (14.6%).
  • Further study of prognostic factors in larger numbers of patients and built into prospective randomised trials may allow the creation of a prognostic model and guide the development of future clinical trials of targeted therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960814.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Bermudez Wagner KM, Thomas MB, Miyamoto C, Micaily B, Hernandez E: Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA). J Clin Oncol; 2009 May 20;27(15_suppl):e16511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA).
  • We conducted an outcome analysis of clinical stage I endometrioid endometrial adenocarcinoma (EEA) patients who underwent surgery with tailored LND and adjuvant therapy (radiation (RT) or chemotherapy) between 1997 and 2008.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Rollins-Raval M, Byler Dann R, Edwards RP, Chivukula M: Clinical outcome in patients with endometrial papillary serous and endometrioid carcinomas as related to WT-1, Pax-2, and p16 immunohistochemical expression profiles. J Clin Oncol; 2009 May 20;27(15_suppl):e16547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome in patients with endometrial papillary serous and endometrioid carcinomas as related to WT-1, Pax-2, and p16 immunohistochemical expression profiles.
  • : e16547 Background: Endometrial papillary serous carcinoma (EPS) can be difficult to differentiate histologically from high grade endometrial endometrioid carcinoma (EE).
  • This finding is now being evaluated in the additional cases.
  • Strong Pax-2 staining in three cases of EPS with better outcome is an interesting finding that deserves further investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960817.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Dizon DS, Stuckey A, Schwartz J: Pegylated liposomal doxorubicin in recurrent serous carcinoma of the uterus. J Clin Oncol; 2009 May 20;27(15_suppl):e16538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegylated liposomal doxorubicin in recurrent serous carcinoma of the uterus.
  • : e16538 Background: Serous carcinoma of the uterus behaves in a much more aggressive fashion than endometrioid tumors of the uterus with risks almost equivalent to ovarian cancers.
  • Given this, we were interested in seeing if pegylated liposomal doxorubicin had a differential benefit in serous cancers of the uterus when compared to endometrioid carcinomas.
  • METHODS: Patients with recurrent serous and endometrioid uterine cancer treated with pegylated liposomal doxorubicin between 1999 and 2007 were identified.
  • RESULTS: Twenty-three patients with recurrent serous histology and 24 with endometrioid histology were identified.
  • The median age at diagnosis in the serous group was 70 (45-89) and 62 (37-94) in the endometrioid cohort.
  • There was no difference between the serous and endometrioid cohorts by stage with advanced disease in 65% and 73%, respectively (p = 0.95).
  • The median PFS was 4.6 months in the serous cohort and 4.7 months in the endometrioid group (p = 0.47).
  • The median overall survival in the serous group was 9.8 months and in the endometrioid group it was 9.6 months (p > 0.5).
  • CONCLUSIONS: We did not find a difference in survival endpoints in women with serous versus endometrioid histologies.
  • While pegylated liposomal doxorubicin appears to be equally active in these groups, survival is uniformly poor in the context of recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960777.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Qian B, Ke PQ, Wang L, Liu WJ, Li MX: [Expression and methylation of adenomatous polyposis coli gene in endometrioid adenocarcinoma]. Ai Zheng; 2008 Jun;27(6):585-9
Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and methylation of adenomatous polyposis coli gene in endometrioid adenocarcinoma].
  • BACKGROUND & OBJECTIVE: Endometrial carcinoma is a common malignant tumor of female reproductive system, with an increasing incidence in China.
  • This study was to observe the expression and DNA methylation of APC gene in endometrioid adenocarcinoma, and explore its correlations to the occurrence and development of this disease.
  • METHODS: The methylation, mRNA and protein expression of APC gene were detected by methylation-specific polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry in 30 specimens of normal proliferative endometrium, 30 specimens of atypical hyperplastic endometrium and 60 specimens of endometrioid adenocarcinoma.
  • RESULTS: The methylation rate of APC gene was significantly higher, the positive rates of APC mRNA and protein were significantly lower in endometrioid adenocarcinoma than in atypical hyperplastic endometrium and normal proliferative endometrium (65.0% vs. 33.3% and 23.3%, 33.3% vs. 63.3% and 73.3%, 30.0% vs. 50.0% and 66.7%,P<0.05).
  • CONCLUSION: The expression and DNA methylation of APC gene are certainly related with the occurrence and development of endometrioid adenocarcinoma.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / genetics. Carcinoma, Endometrioid / genetics. DNA Methylation. Endometrial Neoplasms / genetics
  • [MeSH-minor] Female. Humans. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570730.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / RNA, Messenger
  •  go-up   go-down


22. Ferchichi L, Rammeh-Rommani S, Ben Hammouda S, Sfar R, Farah F, Ben Jilani S, Zermani R: [Endometrioid adenocarcinoma of the uterine cervix associated with mucinous ovarian cystadenocarcinoma]. Gynecol Obstet Fertil; 2006 May;34(5):410-2
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrioid adenocarcinoma of the uterine cervix associated with mucinous ovarian cystadenocarcinoma].
  • [Transliterated title] Association d'un adénocarcinome du col de type endométrioïde à un cystadénocarcinome mucineux de l'ovaire.
  • The authors report the case of a 40-year-old woman, who was operated for an ovarian mucinous cystadenocarcinoma.
  • The pathologic findings of the hysterectomy specimen with bilateral salpingoophorectomy showed an ovarian mucinous cystadenocarcinoma associated with an endometrioid adenocarcinoma of the uterine cervix.
  • The mucinous cystadenocarcinoma represents the third most common type of ovarian carcinoma.
  • In the literature, this tumor had been found in association with endocervical adenocarcinoma or with minimal deviation adenocarcinoma (adenoma malignum) of the uterine cervix.
  • However, its association with an endometrioid adenocarcinoma, to our knowledge, has not been reported.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Hysterectomy


23. Lou HY, Lin kQ, Ye DF, Xie X, Yu X: [Possibility of PTEN expression on predicting pathologic risk factors of endometrioid adenocarcinoma before operation]. Ai Zheng; 2005 Jun;24(6):748-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Possibility of PTEN expression on predicting pathologic risk factors of endometrioid adenocarcinoma before operation].
  • BACKGROUND & OBJECTIVE: Fully estimating pathologic risk factors is important for selecting operation and predicting prognosis for endometrioid adenocarcinoma.
  • Phosphatase and tension homology deleted on chromosome ten (PTEN), taken as the housekeeping gene of endometrium, has the highest mutation rate in endometrioid adenocarcinoma.
  • This study was to investigate the effect of PTEN on predicting pathologic risk factors of endometrioid adenocarcinoma before operation.
  • METHODS: Clinicopathologic data of 107 patients with endometrioid adenocarcinoma were retrospectively analyzed.
  • RESULTS: Deletion rate of PTEN was 56.1% in the 107 endometrioid adenocarcinoma patients.
  • CONCLUSION: Detection of PTEN can't predict the high risk factors of endometrioid adenocarcinoma before operation.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. PTEN Phosphohydrolase / metabolism
  • [MeSH-minor] Adult. Cell Differentiation. Female. Humans. Hysterectomy / methods. Lymphatic Metastasis. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946494.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


24. Razorenova TS, Samsonova EA, Pozharisskiĭ KM, Razorenov GI: [Mathematical evaluation of prognostic significance of clinico-morphological and immunohistochemical features of endometrioid adenocarcinoma]. Vopr Onkol; 2007;53(6):682-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mathematical evaluation of prognostic significance of clinico-morphological and immunohistochemical features of endometrioid adenocarcinoma].
  • Complex examination was given to 76 patients with endometrioid adenocarcinoma and immunohistochemical parameters of estrogen and progesterone receptors, proliferative index (Ki-67), HER2 oncoprotein and clinico-morphological characteristics were entered into Excel database.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / pathology
  • [MeSH-minor] Aged. Cell Differentiation. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Lymphatic Metastasis. Mathematical Computing. Menopause. Middle Aged. Models, Theoretical. Neoplasm Recurrence, Local / chemistry. Neoplasm Recurrence, Local / pathology. Predictive Value of Tests. Prognosis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416138.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


25. Dvalishvili I, Charkviani L, Turashvili G, Burkadze G: Clinical characteristics of prognostic factors in uterine endometrioid adenocarcinoma of various grade. Georgian Med News; 2006 Mar;(132):24-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of prognostic factors in uterine endometrioid adenocarcinoma of various grade.
  • The aim of this study was to compare clinical characteristics of prognostic factors in uterine endometrioid adenocarcinoma of various grades.
  • We have studied 104 postmenopausal women with a histological diagnosis of uterine endometrioid adenocarcinoma.
  • Staging and grading of primary tumor were done according to FIGO system.
  • The following factors were examined: family history of cancer, presence of obesity and vaginal bleeding, recurrence rate within the two years of the study (disease-free periods), vessel permeation, muscle invasion (<1/3, 2/3, >2/3), cervical involvement, lymph node metastasis, ascites cell analysis, parametrium invasion, adnexal metastasis, CA125 pre-surgery values.
  • Histological examination has showed grade 1 endometrioid adenocarcinoma in 35 cases (33,7%, group 1), grade 2 adenocarcinoma in 44 cases (42,3%, group 2), and grade 3 adenocarcinoma in 25 cases (24%, group 3).
  • Most of the factors we have examined seem to be associated with histological grade of uterine endometrioid carcinoma.
  • The analysis of clinicopathological prognostic factors in G1 endometrioid adenocarcinoma cases has showed that about half of these patients are obese, vaginal bleeding is not common, no cervical involvement, parametrium invasion, adnexal metastasis and vessel permeation at the time of diagnosis, no recurrence within two years, pre-surgery value of CA125 is normal, and myometrial invasion is less than 1/3.
  • G3 endometrioid adenocarcinoma cases have showed family history of endometrial cancer, more than half of the patients were obese, with uncommon vaginal bleeding and positive peritoneal cytology, but cervical involvement, parametrium invasion, adnexal metastasis and vessel permeation are present at the time of diagnosis, pre-surgery value of CA125 is high, and myometrial invasion is 2/3 or more than 2/3 in majority of cases, furthermore, in some cases recurrent tumors were developed within two years.
  • G2 endometrioid adenocarcinoma can be considered as an intermediary form which should be managed according to the clinical stage.
  • The results lead to conclude that the histological grade of uterine endometrioid adeno carcinoma seems to be an important independent prognostic indicetor as it is strongly associated with other clinical pathological prognostic factors.
  • [MeSH-major] Carcinoma, Endometrioid / radiotherapy. Carcinoma, Endometrioid / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Postmenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636372.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


26. Kauppila S, Altinörs M, Väre P, Liakka A, Knuuti E, Nissi R: Primary sex cord-like variant of endometrioid adenocarcinoma arising from endometriosis. APMIS; 2008 Sep;116(9):842-5
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sex cord-like variant of endometrioid adenocarcinoma arising from endometriosis.
  • Endometriosis, a relatively common disease generally affecting women in the reproductive age group, is mostly found in the pelvic organs.
  • Although endometriosis is a benign disease, some malignant tumors have been reported to develop in endometriotic lesions, most commonly in the ovary.
  • The relationship between endometriosis and malignancy is not well known, but the majority of endometriosis-associated ovarian malignancies are usually endometrioid adenocarcinomas and clear cell carcinomas.
  • The sex cord-like variant of endometrioid adenocarcinoma is a rare tumor that histologically closely resembles the sex cord-stromal tumor.
  • Despite its rarity, the correct histological diagnosis of the sex cord-like variant of endometrioid adenocarcinoma is crucial to avoid misdiagnosis of a less aggressive tumor.
  • We here report a 53-year-old woman who was diagnosed as having this very rare subtype of endometroid adenocarcinoma curiously arising from an endometriotic lesion at the site of previous salpingo-oophorectomy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology
  • [MeSH-minor] Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024607.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


27. Hayasaka T, Nakahara K, Kojimahara T, Saito-Sekiguchi M, Motoyama T, Kurachi H: Endometrioid adenocarcinoma with a functioning stroma. J Obstet Gynaecol Res; 2007 Jun;33(3):381-3
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma with a functioning stroma.
  • A case of a 70-year-old woman with endometrioid adenocarcinoma of the ovary with functioning stroma is presented.
  • The surgical specimens consisted of a multilocular cystic ovarian tumor of 95 mm in diameter and an enlarged uterus.
  • The diagnosis of endometrial adenocarcinoma of the ovary with functioning stroma was made.
  • Mucinous epithelial ovarian tumors most commonly present with estrogenic stroma, although the frequency of endometrioid adenocarcinoma with functioning stroma is very low.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Estradiol / blood. Follicle Stimulating Hormone / blood. Ovarian Neoplasms / pathology. Ovary / pathology
  • [MeSH-minor] Aged. Female. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578372.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


28. Mamat S, Ikeda J, Enomoto T, Ueda Y, Rahadiani N, Tian T, Wang Y, Qiu Y, Kimura T, Aozasa K, Morii E: Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma. Oncol Rep; 2010 May;23(5):1221-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma.
  • High level of CDCP1 expression proved to be a poor prognosticator for lung adenocarcinoma.
  • Here, expression level of CDCP1 was immunohistochemically examined in 110 cases (median age of 54.7 years) of endometrioid adenocarcinoma, and its clinical implications were evaluated.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cell Adhesion Molecules / analysis. Endometrial Neoplasms / chemistry. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Proportional Hazards Models. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20372833.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDCP1 protein, human; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


29. Miyakuni Y, Matsumoto T, Arakawa A, Sonoue H, Suzuki C, Takeda S: Lymphatic invasion according to D2-40 immunostaining is a predictor of nodal metastasis in endometrioid adenocarcinoma of the uterine corpus. Pathol Int; 2008 Aug;58(8):471-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic invasion according to D2-40 immunostaining is a predictor of nodal metastasis in endometrioid adenocarcinoma of the uterine corpus.
  • In endometrioid adenocarcinoma of the uterine corpus, nodal metastasis is related to prognosis.
  • D2-40 immunostaining has recently been used to detect lymphatic invasion, but a study of D2-40 immunostaining for endometrioid adenocarcinoma of the uterine corpus has not been published.
  • Therefore, as a predictor of nodal metastasis in endometrioid adenocarcinoma of the uterine corpus, the detection of lymphatic invasion on D2-40 immunostaining and lymphovascular invasion on HE stain was compared.
  • A total of 104 cases of invasive endometrioid adenocarcinoma of the uterine corpus, in which the tumor was located in the uterus, were examined on immunohistochemistry using D2-40.
  • In conclusion, lymphatic invasion demonstrated on D2-40 immunostaining is very useful as a predictor for nodal metastasis in endometrioid adenocarcinoma of uterine corpus.
  • [MeSH-major] Antibodies, Monoclonal / analysis. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Female. Humans. Immunoenzyme Techniques. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Lymphocytes, Tumor-Infiltrating / metabolism. Lymphocytes, Tumor-Infiltrating / pathology. Neoplasm Invasiveness. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705765.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


30. Akcaer M, Milman T, Finger PT: Imaging of endometrioid adenocarcinoma of the uterus metastatic to the ciliary body. Ophthalmic Surg Lasers Imaging; 2008 May-Jun;39(3):246-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of endometrioid adenocarcinoma of the uterus metastatic to the ciliary body.
  • A 60-year-old woman with endometrioid adenocarcinoma (stage FIGO II) presented with left eye pain.
  • Positron emission tomography and computed tomography fusion revealed multifocal metastatic disease.
  • A Finger iridectomy technique ciliary body tumor biopsy revealed metastatic endometrioid adenocarcinoma.
  • Treatment with external beam radiation therapy (3,060 cGy in 17 daily fractions) resolved her ocular disease.
  • This is the first reported case of endometrioid adenocarcinoma of the uterus metastatic to the uveal tract.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / secondary. Ciliary Body. Endometrial Neoplasms / pathology. Uveal Neoplasms / diagnosis. Uveal Neoplasms / secondary
  • [MeSH-minor] Brain Neoplasms / secondary. Fatal Outcome. Female. Humans. Microscopy, Acoustic. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556953.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Geisler JP, Linnemeier GC, Manahan KJ: Pelvic and para-aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium. Int J Gynaecol Obstet; 2007 Jul;98(1):39-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic and para-aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium.
  • BACKGROUND: The purpose is to determine the rate of lymph node metastases in women with endometrioid adenocarcinoma of the endometrium (EAE) undergoing systematic lymphadenectomy.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Lymph Node Excision. Lymphatic Metastasis / pathology
  • [MeSH-minor] Female. Humans. Incidence. Para-Aortic Bodies. Pelvis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490668.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Nomoto K, Hori T, Kiya C, Fukuoka J, Nakashima A, Hidaka T, Saito S, Mikami Y, Tsuneyama K, Takano Y: Endometrioid adenocarcinoma of the vagina with a microglandular pattern arising from endometriosis after hysterectomy. Pathol Int; 2010 Sep;60(9):636-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma of the vagina with a microglandular pattern arising from endometriosis after hysterectomy.
  • Primary endometrioid adenocarcinoma rarely occurs in the vagina.
  • Occasionally, endometrioid adenocarcinoma has a microglandular pattern.
  • Herein, a case of primary endometrioid adenocarcinoma of the vagina with a microglandular pattern arising from pre-existing endometriosis long after a hysterectomy, is described.
  • A portion of residual endometrioid adenocarcinoma was identified adjacent to foci of endometriosis in the vaginectomy specimen.
  • The patient has done well without evidence of recurrent disease for 1 year after surgery.
  • Pathologists are encouraged to be aware of the occurrence of endometrioid adenocarcinoma associated with endometriosis in the vaginal stump after hysterectomy, and microglandular morphology which might be a source of misinterpretation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Endometriosis / surgery. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Hysterectomy. Middle Aged


33. Dvalishvili I, Charkviani L, Charkviani T, Turashvili G, Burkadze G: Clinical prognostic factors and expression of cathepsin D in endometrioid adenocarcinoma. Georgian Med News; 2005 Sep;(126):27-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical prognostic factors and expression of cathepsin D in endometrioid adenocarcinoma.
  • The aim of our study was to evaluate the association between the expression of cathepsin D and clinical prognostic data in endometrioid adenocarcinoma of different histological grade.
  • We studied 104 postmenopausal women with diagnosis of endometrioid adenocarcinoma.
  • Histological grade of cancer was assessed by FIGO grading system.
  • Histological study by hematoxylin and eosin showed grade 1 endometrioid carcinoma in 35 cases (33,7%, group 1), grade 2 in 44 cases (42,3%, group 2), grade 3 in 25 cases (24%, grade 3).
  • Our results suggest that the expression of cathepsin D is associated with the higher histological grade of endometrioid adenocarcinoma, depth of myometrial invasion, lymph node positivity, coexistence of obesity and vaginal bleeding.
  • It seems that local invasion and metastatic spread of tumor should be preceeded by the expression of cathepsin D in stromal cells which can be assessed in grade 1 and 2 endometrioid adenocarcinomas.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cathepsin D / metabolism. Endometrial Neoplasms / metabolism
  • [MeSH-minor] Adult. Female. Humans. Obesity / epidemiology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234588.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


34. Bassarak N, Blankenstein T, Brüning A, Dian D, Bergauer F, Friese K, Mylonas I: Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium? BMC Cancer; 2010;10:224

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?
  • Although lymph node metastases are important prognostic parameters, it has been contentious whether a pelvic lymph node dissection itself has a prognostic impact in the treatment of endometrial cancer, especially in endometrioid adenocarcinoma.
  • Therefore, this study evaluated whether lymphadenectomy has a prognostic impact in patients with endometrioid adenocarcinoma.
  • METHODS: The benefits of lymphadenectomy were examined in 214 patients with a histological diagnosis of endometrial adenocarcinoma.
  • RESULTS: Of the 214 patients with endometrial adenocarcinoma, 171 (79.9%) were classified as FIGO stage I, 15 (7.0%) FIGO stage II, 21 (9.8%) FIGO stage III and 7 (3.3%) FIGO stage IV.
  • Only 11 (5.1%) patients showed metastatic disease in the lymph nodes.
  • The performance of a lymphadenectomy resulted in significantly increased cause-specific and overall survival, while progression-free survival was not affected by this operative procedure.
  • CONCLUSIONS: The performance of an operative lymphadenectomy resulted in better survival of patients with endometrioid adenocarcinoma.
  • Therefore, even in endometrioid adenocarcinoma, a pelvic and/or para-aortic lymphadenectomy should be performed.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Lymph Node Excision. Lymph Nodes / surgery
  • [MeSH-minor] Aged. Chi-Square Distribution. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Registries. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):139-44 [11161851.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1304-14 [19231155.001]
  • [Cites] Oncologist. 2003;8(6):541-52 [14657533.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):518-25 [14675670.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):2073-8 [15274403.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):29-33 [7821843.001]
  • [Cites] Am J Obstet Gynecol. 1997 Apr;176(4):777-88; discussion 788-9 [9125601.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3668-75 [15738538.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):92-7 [16406063.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43 [17161155.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):150-6 [17197012.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2434-44 [17911007.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18(2):255-61 [17624991.001]
  • [Cites] Am J Obstet Gynecol. 2008 Apr;198(4):457.e1-5; discussion 457.e5-6 [18395039.001]
  • [Cites] Acta Obstet Gynecol Scand. 2008;87(12):1361-9 [18951214.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):125-36 [19070889.001]
  • [Cites] Gynakol Geburtshilfliche Rundsch. 2003 Apr;43(2):104-10 [12649583.001]
  • (PMID = 20492712.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2891635
  •  go-up   go-down


35. Li HW, Leung SW, Chan CS, Yu MM, Wong YF: Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncol Rep; 2007 Feb;17(2):393-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of maspin in endometrioid adenocarcinoma of endometrium.
  • Underexpression of maspin has been reported in breast and prostatic cancers, but in some cancers such as ovarian, colorectal and pancreatic carcinoma, it was found to be up-regulated.
  • This study aimed at demonstrating the expression of maspin in human endometrial tissue and searching for any altered expression in endometrioid adenocarcinoma of the endometrium compared to normal endometrium.
  • The expression level of the maspin gene was studied using reverse transcriptase-polymerase chain reaction (RT-PCR) performed on RNA extracted from 34 endometrial cancer samples (including 24 with FIGO stage I disease and 10 with FIGO stage III disease) and 28 normal endometrium in proliferative or secretory phases.
  • Our results suggested that there is up-regulated expression of maspin in endometrioid endometrial adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Gene Expression Regulation, Neoplastic. Serpins / biosynthesis
  • [MeSH-minor] Cell Nucleus / metabolism. Cytoplasm / metabolism. DNA Primers / chemistry. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203179.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


36. Abe A, Furumoto H, Yoshida K, Nishimura M, Irahara M, Kudo E, Sano T: A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):168-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component.
  • Endometrioid adenocarcinoma of the ovary coexists very rarely with yolk sac tumor (YST).
  • This unusual mixed tumor is thought to be a rare variant of endometrioid ovarian carcinoma because of its aggressive behavior, lack of response to chemotherapy, and unfavorable prognosis.
  • We report a case of ovarian endometrioid adenocarcinoma with a YST component in a postmenopausal woman.
  • Cytokeratin7 and epithelial membrane antigen were negative in YST, but positive in endometrioid adenocarcinoma.
  • The occurrence of this unusual case suggests that even somatic carcinomas may acquire an extraembryonal germ cell differentiation.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bridged Compounds / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Immunoenzyme Techniques. Middle Aged. Platinum / administration & dosage. Taxoids / administration & dosage. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466041.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 1605-68-1 / taxane; 49DFR088MY / Platinum; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


37. Körner M, Burckhardt E, Mazzucchelli L: Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: A possible link to endometrioid adenocarcinoma. Mod Pathol; 2006 Dec;19(12):1615-23
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: A possible link to endometrioid adenocarcinoma.
  • Endometriosis may progress to invasive endometrioid adenocarcinoma, particularly in the ovary.
  • Therefore, in this study, extragonadal endometriosis (n = 10), ovarian endometriosis without malignancy (n = 10), ovarian endometriosis with direct transition into endometrioid adenocarcinoma (n = 8), and normal endometrium (n = 12) were investigated for numerical chromosomal aberrations by fluorescence in situ hybridization using centromere enumeration probes.
  • Trisomies 1 and 7, and monosomies 9 and 17 were found in endometriosis, ovarian endometrioid adenocarcinoma, and normal endometrium.
  • The proportions of aneusomic cells were significantly higher in ovarian endometrioid carcinoma compared with ovarian endometriosis (P < 0.001), and in ovarian endometriosis compared with extragonadal endometriosis and normal endometrium (P < 0.001).
  • The data provide new evidence of a common lineage of endometriosis and ovarian endometrioid carcinoma.
  • The higher frequency of chromosomal aberrations in endometrioid carcinoma than in endometriosis may reflect an expansion of aberrant cell clones already present in endometriosis during the progression to cancer.
  • [MeSH-major] Aneuploidy. Carcinoma, Endometrioid / genetics. Endometriosis / genetics. Ovarian Neoplasms / genetics. Precancerous Conditions / genetics
  • [MeSH-minor] Centromere / genetics. DNA, Neoplasm / analysis. Endometrium / pathology. Female. Humans. In Situ Hybridization, Fluorescence

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980942.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


38. Nishimura N, Hachisuga T, Yokoyama M, Iwasaka T, Kawarabayashi T: Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary. J Obstet Gynaecol Res; 2005 Apr;31(2):120-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary.
  • METHODS: Thirty-six patients with gross tumors confined to the pelvis and of endometrioid adenocarcinoma subtype in both the endometrium and ovary were selected from our file of 546 Japanese women with endometrial carcinoma.
  • CONCLUSION: When encountering women with coexisting endometrioid carcinoma in the endometrium and ovary with gross tumor limited to the pelvis, more attention should be paid to LVSI of the tumor of the uterus as a poor prognostic indicator.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Middle Aged. Neoplasm Invasiveness. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771637.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Fischer G, Odunsi K, Lele S, Mhawech P: Ovarian primary primitive neurectodermal tumor coexisting with endometrioid adenocarcinoma: a case report. Int J Gynecol Pathol; 2006 Apr;25(2):151-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian primary primitive neurectodermal tumor coexisting with endometrioid adenocarcinoma: a case report.
  • We report an unusual case of a 78-year-old woman with primary ovarian tumor that consisted of primitive neurectodermal tumor and endometrioid adenocarcinoma.
  • The patient presented with abdominal pain and weight loss and had disseminated disease at her initial presentation.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Neoplasms, Multiple Primary. Neuroectodermal Tumors, Primitive. Ovarian Neoplasms
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633064.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol; 2008 Aug;110(2):196-201
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
  • OBJECTIVE: Tumor markers with increased sensitivity and specificity for endometrial cancer are needed to help monitor response to therapy and to detect recurrent disease.
  • The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus.
  • METHODS: Pre-operative serum samples from surgically staged patients with endometrioid adenocarcinoma of the uterus were analyzed for levels of HE4, SMRP, CA72-4 and CA125.
  • For stage I disease, HE4 yielded a 17.1% improvement in sensitivity compared with CA125.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Endometrial Neoplasms / blood. Epididymal Secretory Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Tumor-Associated, Carbohydrate / blood. CA-125 Antigen / blood. Female. GPI-Linked Proteins. Humans. Membrane Glycoproteins / blood. Middle Aged. Neoplasm Staging. Sensitivity and Specificity. beta-Defensins

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):28-33 [12079296.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):201-9 [12713981.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1195-7 [12748476.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):636-43 [15253447.001]
  • [Cites] Am J Obstet Gynecol. 1984 Apr 15;148(8):1057-8 [6201072.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Biometrics. 1988 Sep;44(3):837-45 [3203132.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):292-7 [8088605.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):321-6 [8088608.001]
  • [Cites] Am J Obstet Gynecol. 1996 Apr;174(4):1316-9 [8623863.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):141-6 [8995563.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):967-70 [9038731.001]
  • [Cites] Gynecol Oncol. 1997 May;65(2):291-6 [9159340.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):441-7 [9277659.001]
  • [Cites] Cancer Detect Prev. 1999;23(5):397-400 [10468891.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(4):315-7 [10475131.001]
  • [Cites] J Reprod Med. 2005 Aug;50(8):585-90 [16220763.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5 [12144685.001]
  • (PMID = 18495222.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-72-4 antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / beta-Defensins; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS243878; NLM/ PMC3594093
  •  go-up   go-down


41. Xiong Y, Xiong YY, Zhou YF: Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma. Eur J Gynaecol Oncol; 2010;31(2):160-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma.
  • OBJECTIVE: The aim of this study was to explore the potentiality of beta-catenin, Glut-1 and PTEN proteins as markers for a diagnosis of endometrial intraepithelial neoplasia (EIN).
  • DESIGN: Ten proliferative endometrium, 83 endometrial hyperplasia (59 benign hyperplasia, 24 EIN) and 24 endometrioid adenocarcinoma sections were immunostained for beta-catenin, Glut-1 and PTEN protein expression. RESULTS:.
  • (1) Abnormal expression of beta-catenin was detected in 10% of benign hyperplasia, 50% of EIN and 67% of endometriold adenocarcinoma. (2) Overexpression of Glut-1 was present in 58% of EIN and 71% of endometrioid adenocarcinoma. (3) Complete loss of PTEN immunoreactivity was found in 20% of proliferative endometrium, 29% of benign hyperplasia, 38% of EIN and 63% of endometrioid adenocarcinoma.
  • CONCLUSIONS: The abnormal expression of beta-catenin and overexpression of Glut-1 may be useful markers in distinguishing benign hyperplasia from EIN, whereas lack of PTEN expression is not an appropriate marker for a diagnosis of EIN.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Glucose Transporter Type 1 / metabolism. PTEN Phosphohydrolase / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20527231.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / beta Catenin; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


42. Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T: Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer; 2009 May 1;115(9):1867-74
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma.
  • BACKGROUND: : The objective of this study was to determine the efficacy of mifepristone (RU-486) in women with advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS).
  • METHODS: : Mifepristone (RU-486; 200 mg orally) was given daily to patients with progesterone receptor-positive advanced or recurrent endometrioid adenocarcinoma or LGESS.
  • Stable disease was noted in 3 of 12 patients (at 8 weeks, 12 weeks, and > or =77 weeks, respectively), and the median time to disease progression was 48 days.
  • Among the patients who had stable disease, 2 women had endometrioid endometrial cancer, and 1 woman had LGESS.
  • CONCLUSIONS: : Single-agent mifepristone used in the treatment of recurrent endometrioid adenocarcinoma or LGESS resulted in a stable disease rate of 25%.
  • One patient who had a biopsy-positive disease recurrence remained stable at 77 weeks.
  • Recently, was been recognized that biologic agents used as single agents may result only in stable disease unless they are combined with cytotoxic agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Carcinoma, Endometrioid / drug therapy. Hormone Antagonists / therapeutic use. Mifepristone / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Receptors, Progesterone / metabolism. Recurrence

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241422.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA098258
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Receptors, Progesterone; 320T6RNW1F / Mifepristone
  •  go-up   go-down


43. Montalto SA, Hakmi A, Moth P, Raju KS, Coutts M, Papadopoulos AJ, Devaja O: Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case? Eur J Gynaecol Oncol; 2009;30(1):35-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case?
  • OBJECTIVE: The purpose of this study was to investigate what proportion of cases showing a well differentiated endometrioid endometrial adenocarcinoma in the hysterectomy specimen removed at two UK cancer centres had adverse pathological features or advanced stage disease at the time of presentation.
  • STUDY DESIGN: Ninety-eight patients who were operated on at either the South East London Cancer Centre, London or the Kent Oncology Centre, Maidstone had a histological diagnosis of well differentiated (grade 1) endometrioid adenocarcinoma in their hysterectomy specimen.
  • RESULTS: Of the initial 98 cases, 65 patients (66.3%) were referred with a preoperative curettage showing a well differentiated endometrioid adenocarcinoma, 25 cases (25.5%) were referred with atypical endometrial hyperplasia, seven patients (7.1%) were referred with a moderately differentiated endometrioid adenocarcinoma, and one case (1.0%) was referred with a possible malignant mixed Mullerian tumour.
  • Subsequent histological examination of the hysterectomy specimens revealed that all of these cases had a well differentiated endometrioid adenocarcinoma.
  • From our study, 33.6% of cases with a well differentiated endometrioid adenocarcinoma of the uterus were Stage Ic or more at the time of presentation; 12.2% were at least FIGO Stage Ic, eight patients (8.2%) were FIGO Stage IIa, seven patients (7.1%) were Stage IIb and six patients (6.1%) were Stage III.
  • CONCLUSION: A significant proportion (33.6%) of well differentiated tumours in a hysterectomy were found to have Stage Ic disease or more at the time of presentation, and thus full surgical staging including a lymphadenectomy should have been carried out in these cases.
  • Cases with a preoperative biopsy showing atypical hyperplasia or well differentiated adenocarcinoma should have a preoperative MRI scan or preferably an intraoperative frozen section examination to identify those cases with adverse pathological features which need to be fully staged with pelvic and paraaortic lymphadenectomy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy / methods. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Preoperative Care. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317254.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


44. Healy KA, Carney KJ, Osunkoya AO: Endometrioid adenocarcinoma in the native ureter of a renal transplant patient: case report and review of the literature. ScientificWorldJournal; 2010;10:1714-22
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma in the native ureter of a renal transplant patient: case report and review of the literature.
  • A case of endometrioid adenocarcinoma in the native ureter of a postmenopausal renal transplant patient presented with painless gross hematuria and hydroureteronephrosis.
  • Endoscopic biopsies of the native left ureteral mass showed endometrioid adenocarcinoma, grade II-III.
  • Final pathology confirmed endometrioid adenocarcinoma, grade II-III, arising in a background of endometriosis with negative perirectal lymph nodes.
  • This case of ureteral endometrioid adenocarcinoma highlights the importance of obtaining a careful history and maintaining a high index of suspicion for malignant degeneration, especially in the context of hyperestrogenism.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Kidney Transplantation. Ureter / pathology
  • [MeSH-minor] Endometriosis / complications. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842317.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


45. Kobayashi S, Sasaki M, Goto T, Asakage N, Sekine M, Suzuki T, Tsukada K, Yamasaki S, Ukawa S: Endometrioid adenocarcinoma arising from endometriosis of the rectosigmoid. Dig Endosc; 2010 Jan;22(1):59-63
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma arising from endometriosis of the rectosigmoid.
  • A case of endometrioid adenocarcinoma supposedly arising from endometriosis of the rectum is reported.
  • [MeSH-major] Adenocarcinoma / etiology. Endometrial Neoplasms / etiology. Endometriosis / complications. Rectal Diseases / complications. Sigmoid Diseases / complications
  • [MeSH-minor] Colonoscopy. Female. Humans. Middle Aged. Ovarian Cysts / complications

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20078668.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 17
  •  go-up   go-down


46. Miyai K, Yamamoto S, Aida S, Shimazaki H, Takano M, Kudoh K, Furuya K, Tamai S, Matsubara O: Massive intra-abdominal undifferentiated carcinoma derived from an endometrioid adenocarcinoma in a "normal-sized" ovary. Int J Gynecol Pathol; 2010 Jul;29(4):321-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive intra-abdominal undifferentiated carcinoma derived from an endometrioid adenocarcinoma in a "normal-sized" ovary.
  • We report a case of massive intra-abdominal undifferentiated carcinoma derived from a tiny well-differentiated endometrioid adenocarcinoma of the ovary.
  • The right ovarian tumor was a histologically well-differentiated endometrioid adenocarcinoma.
  • Both the intra-abdominal undifferentiated tumor and the ovarian adenocarcinoma cells were immunohistochemically positive for keratin AE1/3, Ber-EP4, and CD10.
  • Epithelial membrane antigen was positive only in the ovarian adenocarcinoma component, and vimentin was diffusely positive only in the intra-abdominal undifferentiated tumor component.
  • Allelotype analysis using 24 polymorphic markers located on 12 chromosomal arms showed that the intra-abdominal undifferentiated carcinoma and ovarian adenocarcinoma components had a high concordance rate (88%) of allelic patterns including identical allelic loss patterns at 7 chromosomal loci, suggesting a common genetic lineage.
  • These data suggest that ovarian endometrioid adenocarcinoma, even when small in size, can give rise to a massive undifferentiated carcinoma filling the peritoneal cavity.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Alleles. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Calbindin 2. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Female. Humans. Keratins, Hair-Specific / metabolism. Middle Aged. Mucin-1 / metabolism. Neprilysin / metabolism. Polymerase Chain Reaction. S100 Calcium Binding Protein G / metabolism. Vimentin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567143.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / DNA, Neoplasm; 0 / KRTAP1-3 protein, human; 0 / Keratins, Hair-Specific; 0 / Mucin-1; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 0 / human epithelial antigen-125; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


47. Staats PN, Clement PB, Young RH: Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases. Am J Surg Pathol; 2007 Oct;31(10):1490-501
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases.
  • Vaginal adenocarcinoma is the second most common primary cancer of the vagina, yet there has been very little study of most subtypes other than clear cell carcinoma.
  • We reviewed 18 cases of primary vaginal endometrioid adenocarcinoma, in our experience the second most common subtype.
  • On microscopic examination, each of the tumors had a pure or predominant component of typical endometrioid adenocarcinoma.
  • Other subtypes of adenocarcinoma (such as serous when the tumor has a papillary pattern) and atypical forms of endometriosis, including polypoid endometriosis, are the most common other differential diagnostic considerations.
  • The prognosis seems to be good in low-stage patients, with 11 patients alive and well and 2 alive with recurrent disease.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Cystadenocarcinoma, Serous / diagnosis. Diagnosis, Differential. Endometriosis / complications. Endometriosis / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895749.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Kitajima K, Kaji Y, Kuwata Y, Imanaka K, Sugihara R, Sugimura K: Magnetic resonance imaging findings of endometrioid adenocarcinoma of the ovary. Radiat Med; 2007 Aug 1;25(7):346-54
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging findings of endometrioid adenocarcinoma of the ovary.
  • PURPOSE: We assessed magnetic resonance imaging (MRI) features and clinical characteristics of ovarian endometrioid adenocarcinoma.
  • MATERIALS AND METHODS: A total of 31 patients with 39 surgically proven ovarian endometrioid adenocarcinomas were analyzed retrospectively.
  • CONCLUSION: MRI of ovarian endometrioid adenocarcinomas revealed two types: a solid type and a cystic type.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Magnetic Resonance Imaging / methods. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Contrast Media. Female. Gadolinium DTPA. Humans. Middle Aged. Retrospective Studies. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705005.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


49. Arai T, Watanabe J, Kawaguchi M, Kamata Y, Nishimura Y, Jobo T, Kuramoto H: Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):391-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma.
  • Clear cell adenocarcinoma (CCA) of the endometrium has a poor prognosis, although the biologic features of this rare tumor are not clear.
  • Thirteen cases of CCA were compared with cases of endometrioid adenocarcinoma (EMA) of the endometrium.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Endometrioid / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Cyclin A / analysis. Cyclin D1 / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Tumor Suppressor Protein p53

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445664.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cyclin A; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


50. Gates EJ, Hirschfield L, Matthews RP, Yap OW: Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium. J Natl Med Assoc; 2006 Nov;98(11):1814-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium.
  • OBJECTIVE: To determine if body mass index (BMI) influences tumor expression of HER-2/neu, estrogen and progesterone receptors (ER/PR), and survival in women with endometrial adenocarcinoma.
  • METHODS: Patients diagnosed between January 1992 and December 2001 with endometrioid adenocarcinoma of the uterus were identified.
  • CONCLUSION: In patients with endometrioid adenocarcinoma, low BMI is associated with high stage and tumor expression of HER-2/neu.
  • [MeSH-major] Body Mass Index. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / physiopathology. Endometrial Neoplasms / mortality. Endometrial Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis. Receptor, ErbB-2 / genetics. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1979 Sep;54(3):269-77 [471366.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1055-60 [333120.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):1140-7 [6936073.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):388-93 [11606102.001]
  • [Cites] JAMA. 1980 Nov 28;244(21):2419-22 [7431569.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):360-8 [16633364.001]
  • [Cites] Int J Epidemiol. 2006 Feb;35(1):151-8 [16278243.001]
  • [Cites] Am J Epidemiol. 2005 May 15;161(10):939-47 [15870158.001]
  • [Cites] Cancer. 1949 Nov;2(6):964-71, illust [15395195.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):138-43 [10202671.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):25-9 [9577367.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5077-85 [9371506.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):138-42 [9103403.001]
  • [Cites] Cancer Lett. 1996 Jan 2;98(2):151-5 [8556702.001]
  • [Cites] Am J Obstet Gynecol. 1995 Dec;173(6):1829-34 [8610771.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5693-8 [7585656.001]
  • [Cites] Nutr Cancer. 1995;23(2):141-9 [7644383.001]
  • [Cites] Am J Obstet Gynecol. 1994 Nov;171(5):1193-8 [7977518.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1604-7 [8137266.001]
  • [Cites] Gynecol Oncol. 1993 Feb;48(2):196-202 [8428691.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2157-62 [7127255.001]
  • [Cites] Pathol Res Pract. 1982 Aug;174(3):237-56 [7145769.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Obstet Gynecol. 1984 Jul;64(1):1-11 [6738931.001]
  • [Cites] Cancer Treat Rep. 1985 Feb;69(2):237-8 [3971394.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1452-5 [4027879.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Am J Obstet Gynecol. 1988 Apr;158(4):796-807 [2966586.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):364-6 [2227549.001]
  • [Cites] Rev Fr Gynecol Obstet. 1990 Oct;85(10):513-6 [2263829.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):15-21 [1670908.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):179-85 [1361478.001]
  • (PMID = 17128692.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2569783
  •  go-up   go-down


51. Lim MC, Lee SM, Lee J, Choi HJ, Lee S, Huh CY, Park SY: Endometrioid adenocarcinoma in urethrovaginal septum: a diagnostic pitfall. J Korean Med Sci; 2009 Feb;24(1):162-5
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma in urethrovaginal septum: a diagnostic pitfall.
  • Primary endometrioid adenocarcinoma developed at urethrovaginal septum has not been reported.
  • A pinpoint ulceration at slightly elevated anterior vaginal wall was found and biopsy revealed endometrioid adenocarcinoma.
  • Microscopic finding of the pathology revealed endometrioid adenocarcinoma.
  • This is the first reported case of extraovarian endometrioid adenocarcinoma developed at the urethrovaginal septum.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Urethral Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1970 Aug;36(2):251-6 [5428492.001]
  • [Cites] Gynecol Oncol. 1984 Jan;17(1):58-63 [6420243.001]
  • [Cites] Hinyokika Kiyo. 1988 Apr;34(4):696-700 [3041781.001]
  • [Cites] Obstet Gynecol. 2006 Sep;108(3 Pt 2):753-5 [17018491.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(1):39-41 [9476057.001]
  • [Cites] Jpn J Clin Oncol. 2005 Mar;35(3):154-7 [15741306.001]
  • [Cites] Gynecol Oncol. 1989 Aug;34(2):232-6 [2666285.001]
  • (PMID = 19270832.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2650998
  • [Keywords] NOTNLM ; Carcinoma, Endometrioid / Urethrovaginal Septum
  •  go-up   go-down


52. Rasool N, Fader AN, Seamon L, Neubauer NL, Shahin FA, Alexander HA, Moore K, Moxley K, Secord AA, Kunos C, Rose PG, O'Malley DM: Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol; 2010 Jan;116(1):10-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.
  • OBJECTIVE: To study patterns of recurrence and survival outcomes in patients with surgical stage I, grade 3 endometrioid adenocarcinoma of the endometrium (EA) treated with various treatment modalities.
  • Majority of recurrences were not salvaged as 75% (12/16) died of their disease with a median time of recurrence to death of 8 months.
  • CONCLUSIONS: Patients with stage IB/IC, grade 3 endometrioid adenocarcinoma have a significant risk for extra-pelvic recurrence.
  • Most patients will not be salvaged and will succumb to their disease, suggesting that current loco-regional adjuvant treatment strategies are not optimal and evaluation of more systemic therapies is warranted.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2010 Jun;117(3):507; author reply 507-8 [20189231.001]
  • (PMID = 19875158.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


53. Orezzoli JP, Sioletic S, Olawaiye A, Oliva E, del Carmen MG: Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol; 2009 Jun;113(3):316-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
  • OBJECTIVES: Endometrioid adenocarcinoma of the endometrium (EEC) is the most common histologic type of endometrial cancer, with stage being the most critical prognostic factor.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hysterectomy. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19345400.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Kumar VJ, Nin CY, Kuei LY, Tan KH, Yeo R, Lam PY: Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy. Int J Gynecol Cancer; 2010 May;20(4):564-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy.
  • INTRODUCTION: Advanced age, deep myoinvasion, whole cavity or lower uterine segment tumors, poor differentiation, and lymphovascular space invasion are known to increase recurrence risk and adversely affect survival in stage I endometrioid adenocarcinoma of the uterus.
  • METHODS: Data of 162 patients with surgical stage I endometrioid adenocarcinoma of the uterus with an increased risk of recurrence were reviewed from the year 1997 to 2008 at KK Gynaecological Cancer Centre, Singapore.
  • Most patients (54.3%) had surgical stage IC endometrioid adenocarcinoma, whereas the rest had stage IB.
  • Age, lymphovascular space invasion, and tumor volume and location were not significant parameters in surgical stage I endometrioid adenocarcinoma patients who failed.
  • [MeSH-major] Brachytherapy. Carcinoma, Endometrioid / mortality. Endometrial Neoplasms / mortality. Neoplasm Recurrence, Local / mortality. Radiotherapy, Adjuvant / mortality. Uterine Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686374.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Rubatt JM, Slomovitz BM, Burke TW, Broaddus RR: Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. Gynecol Oncol; 2005 Nov;99(2):472-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
  • BACKGROUND: Conservative treatment with progestins is a reasonable treatment option for endometrial complex atypical hyperplasia and, in the experimental setting, for some women with grade 1 endometrial endometrioid adenocarcinoma.
  • More than 2 years after her original diagnosis, she developed endometrial endometrioid adenocarcinoma, FIGO grade 2, with lymph node metastasis.
  • CONCLUSION: Currently, there are no good criteria for predicting which patients with complex atypical hyperplasia/grade 1 endometrioid adenocarcinoma will optimally respond to progestin therapy.
  • In a woman with a biopsy diagnosis of endometrial hyperplasia, evaluation of MLH1 protein status by immunohistochemistry may provide useful information when medical management is being considered.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / drug therapy. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Progestins / therapeutic use
  • [MeSH-minor] Adult. Disease Progression. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099019.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CN / N01-CN-05127
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Progestins
  •  go-up   go-down


56. Mhawech-Fauceglia P, Herrmann FR, Rai H, Tchabo N, Lele S, Izevbaye I, Odunsi K, Cheney RT: IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol; 2010 Jun;133(6):899-908
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma.
  • Differentiating uterine serous carcinoma (USC) from endometrioid adenocarcinoma (EAC) could be problematic, especially in high-grade EACs and tumors exhibiting architectural variations.
  • To address this issue, we evaluated 103 endometrial carcinoma cases using 4 immunomarkers, beta-catenin, IMP3, PTEN, and p53.
  • None of the markers or their combinations demonstrated any value in making the diagnosis of serous component in mixed EAC-USC tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / pathology. PTEN Phosphohydrolase / analysis. RNA-Binding Proteins / analysis. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies. Tumor Suppressor Protein p53 / analysis. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20472848.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / RNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


57. Ohishi Y, Kaku T, Kaneki E, Wake N, Tsuneyoshi M: Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study. Gynecol Oncol; 2007 May;105(2):548-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study.
  • CASE: We herein report the case of a 34-year-old woman with an ovarian tumor which was composed of endometrioid adenocarcinoma (EAC), clear cell adenocarcinoma (CCC), squamous cell carcinoma, yolk sac tumor (YST) and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation.
  • Correct diagnosis of this complex and aggressive tumor is paramount.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Carcinoma, Endometrioid / pathology. Carcinoma, Squamous Cell / pathology. Endodermal Sinus Tumor / pathology. Female. Humans. Neuroectodermal Tumors / pathology. Rhabdomyosarcoma / pathology. Teratoma / pathology


58. Park HM, Lee SS, Eom DW, Kang GH, Yi SW, Sohn WS: Endometrioid adenocarcinoma arising from endometriosis of the uterine cervix: a case report. J Korean Med Sci; 2009 Aug;24(4):767-71
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma arising from endometriosis of the uterine cervix: a case report.
  • Endometrioid adenocarcinoma arising from endometriosis of the uterine cervix is rare in premenopausal woman.
  • A 48-yr-old woman complaining of severe dysmenorrhea was referred for investigation of a pelvic mass.
  • Histological examination revealed an endometrioid adenocarcinoma directly adjacent to the endometriosis at the uterine cervix, with a transition observed between endometriosis and endometrioid adenocarcinoma.
  • The patient was diagnosed as having endometrioid adenocarcinoma arising from endometriosis of the uterine cervix and underwent postoperative chemotherapy.
  • Gynecologists and pathologists should be aware of the difficulties associated with a delay in diagnosis of endometrioid adenocarcinoma arising from endometriosis when the tumor presents as a benign looking endometrioma.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Cervix Uteri / pathology. Endometrial Neoplasms / diagnosis. Endometriosis / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Hysterectomy. Magnetic Resonance Imaging. Middle Aged. Ovariectomy

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):513-24 [10757398.001]
  • [Cites] Obstet Gynecol. 2002 Oct;100(4):788-95 [12383550.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jul;18(3):198-205 [12090586.001]
  • [Cites] Gynecol Oncol. 2002 Aug;86(2):220-2 [12144831.001]
  • [Cites] Int J Gynecol Cancer. 2003 May-Jun;13(3):376-80 [12801273.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):466-71 [12911723.001]
  • [Cites] Cancer. 1972 Jun;29(6):1653-64 [5031251.001]
  • [Cites] Cancer. 1977 Dec;40(6):3065-73 [338141.001]
  • [Cites] Clin Obstet Gynecol. 1980 Sep;23(3):951-63 [7418292.001]
  • [Cites] Acta Obstet Gynecol Scand Suppl. 1981;101:53-8 [6946672.001]
  • [Cites] Fertil Steril. 1983 Apr;39(4):520-4 [6832408.001]
  • [Cites] Am J Obstet Gynecol. 1983 Jun 1;146(3):247-53 [6859132.001]
  • [Cites] Am J Obstet Gynecol. 1987 Oct;157(4 Pt 1):849-56 [3674158.001]
  • [Cites] Obstet Gynecol. 1988 Mar;71(3 Pt 2):444-7 [3279356.001]
  • [Cites] Obstet Gynecol. 1990 Jun;75(6):1023-8 [2188180.001]
  • [Cites] Histopathology. 1991 Feb;18(2):107-14 [2010178.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):443-7 [7835785.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):238-44 [8631545.001]
  • [Cites] Am J Obstet Gynecol. 1997 Mar;176(3):572-9 [9077609.001]
  • [Cites] Diagn Cytopathol. 1997 Mar;16(3):274-80 [9099553.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):559-63 [10507786.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:18-25 [11093057.001]
  • (PMID = 19654969.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2719211
  • [Keywords] NOTNLM ; Carcinoma, Endometrioid / Cervix Uteri / Endometriosis
  •  go-up   go-down


59. Kinugasa Y, Morishige K, Kamiura S, Tsukamoto Y, Saji F: Parathyroid hormone-related protein-secreting uterine endometrioid adenocarcinoma. Jpn J Clin Oncol; 2006 Feb;36(2):113-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid hormone-related protein-secreting uterine endometrioid adenocarcinoma.
  • The diagnosis of parathyroid hormone-related protein (PTHrP)-secreting metastatic uterine endometrioid cancer was made in a 32-year-old Japanese woman with humoral hypercalcemia of malignancy.
  • The primary endometrial cancer had been removed, and the tumor was diagnosed as Grade 1 endometrioid adenocarcinoma with shallow myometrial invasion.
  • To the best of our knowledge, this is the first reported case of hypercalcemia due to PTHrP secretion in uterine endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / chemistry. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / pathology. Hypercalcemia / etiology. Parathyroid Hormone-Related Protein / analysis
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Immunohistochemistry. Japan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418186.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


60. Kawate S, Takeyoshi I, Ikota H, Numaga Y, Sunose Y, Morishita Y: Endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon. Jpn J Clin Oncol; 2005 Mar;35(3):154-7
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon.
  • This report presents a case of endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon following total abdominal hysterectomy and bilateral salpingo-oophorectomy for leiomyoma of the uterus and infiltrating pelvic endometriosis, and hormone replacement therapy.
  • Based on the diagnosis of mesocolonic tumor, sigmoidectomy with lymph node resection was performed.
  • The tumor cells were immunopositive for cytokeratin 7, but negative for cytokeratin 20, and the tumor was histologically diagnosed as endometrioid adenocarcinoma of the mesocolon.
  • [MeSH-major] Carcinoma, Endometrioid / etiology. Endometriosis / pathology. Sigmoid Diseases / pathology. Sigmoid Neoplasms / etiology
  • [MeSH-minor] Cell Transformation, Neoplastic / pathology. Colon, Sigmoid / blood supply. Estrogen Replacement Therapy / adverse effects. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Leiomyoma / surgery. Lymph Node Excision. Mesentery / pathology. Middle Aged. Ovariectomy. Postoperative Period. Uterine Neoplasms / surgery

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741306.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Rauh-Hain JA, Costaaggini I, Olawaiye AB, Growdon WB, Horowitz NS, del Carmen MG: A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy. Eur J Gynaecol Oncol; 2010;31(3):284-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy.
  • OBJECTIVE: To determine the outcomes in patients with Stage I uterine clear cell carcinoma (UCCC) treated with and without adjuvant therapy, and to compare the outcomes in these patients to that of matched controls, patients with Stage I, grade 3, endometrioid adenocarcinoma of the endometrium (EC).
  • Cases (UCCC) were matched by age, stage, adjuvant therapy, and year of diagnosis to controls consisting of patients with grade 3 EC.
  • The 5-year disease-free survival and overall survival rates for the observation and the XRT groups were 78% and 75%, (p = 0.7) and 85% and 82% (p = 0.1), respectively.
  • When compared to controls, the 5-year disease-free survival rates and overall survival rates of patients with Stage I UCCC were not significantly different, 77% vs 75% (p = 0.8) and 84% vs 88% (p = 0.5), respectively.
  • These data question the benefit of radiation therapy in UCCC patients with disease confined to the uterus.
  • [MeSH-major] Adenocarcinoma, Clear Cell / therapy. Carcinoma, Endometrioid / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Chemotherapy, Adjuvant. Endometrial Neoplasms. Female. Humans. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21077469.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


62. Motohara K, Tashiro H, Ohtake H, Saito F, Ohba T, Katabuchi H: Endometrioid adenocarcinoma arising in adenomyosis: elucidation by periodic magnetic resonance imaging evaluations. Int J Clin Oncol; 2008 Jun;13(3):266-70
MedlinePlus Health Information. consumer health - Uterine Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma arising in adenomyosis: elucidation by periodic magnetic resonance imaging evaluations.
  • There are several case reports of adenocarcinomas developing within adenomyosis.
  • However, there is no report demonstrating the natural course from adenomyosis to adenocarcinoma.
  • Eleven years after the initial diagnosis, endometrial cytology revealed the presence of malignant cells.
  • Consequently, we performed a modified radical hysterectomy and pelvic lymph node dissection, under a presumptive diagnosis of adenocarcinoma arising in adenomyosis.
  • Histological diagnosis revealed an endometrioid adenocarcinoma (G3) transformed from adenomyotic epithelium, which was classified, according to the International Federation of Gynecology and Obstetrics, as stage Ic, pT1cN0M0.
  • In this patient, periodic MRI evaluations, in conjunction with pathological examination, identified the transformation from adenomyosis to adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / complications. Endometrial Neoplasms / complications. Endometriosis / complications. Magnetic Resonance Imaging. Uterine Diseases / complications
  • [MeSH-minor] Adult. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18553239.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


63. Panggid K, Cheewakriangkrai C, Khunamornpong S, Siriaunkgul S: Factors related to recurrence in non-obese women with endometrial endometrioid adenocarcinoma. J Obstet Gynaecol Res; 2010 Oct;36(5):1044-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors related to recurrence in non-obese women with endometrial endometrioid adenocarcinoma.
  • AIM: To evaluate the clinicopathological factors associated with recurrence of disease in non-obese women with endometrial endometrioid adenocarcinoma.
  • METHODS: Medical records of the 138 patients who had newly diagnosed endometrial endometrioid adenocarcinoma with body mass index (BMI) <25 and underwent a complete staging surgery between 1999 and 2007 were reviewed.
  • The presence of LVSI, poor histological grade, and advanced stage were found significantly in patients who had disease recurrences (P = 0.026, P < 0.001, and P = 0.015, respectively).
  • CONCLUSION: LVSI, poor histological grade, and advanced stage were associated with disease recurrence in non-obese women with endometrial endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Body Mass Index. Chi-Square Distribution. Disease Progression. Female. Humans. Hysterectomy. Kaplan-Meier Estimate. Medical Records. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21058438.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


64. Fujiwara H, Saga Y, Takahashi K, Ohwada M, Enomoto A, Konno R, Tanaka A, Suzuki M: Omental metastases in clinical stage I endometrioid adenocarcinoma. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):165-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omental metastases in clinical stage I endometrioid adenocarcinoma.
  • The clinical benefit of an omentectomy in endometrioid adenocarcinoma is unclear.
  • The objective of this study was to clarify the significance of an omentectomy performed for clinical stage I endometrioid adenocarcinoma.
  • A prospective study was performed on 134 patients with clinical stage I endometrioid adenocarcinoma who underwent omentectomy in addition to a staging laparotomy between 1998 and 2004: simple total hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymph node dissection, and peritoneal cytology.
  • The omental metastases rate for clinical stage I endometrioid adenocarcinoma was lower than the positive rates for extrauterine spread to other sites; thus, the routine application of omentectomy as a part of a staging laparotomy may not be efficacious.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Omentum / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Nodes. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466052.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Dvalishvili I, Charkviani L, Turashvili G, Burkadze G: The expression of cadherin e and clinical prognostic factors in uterine endometrioid adenocarcinoma. Georgian Med News; 2005 Nov;(128):17-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of cadherin e and clinical prognostic factors in uterine endometrioid adenocarcinoma.
  • The aim of our study was to evaluate the association between the expression of E-cadherin and clinical prognostic factors in uterine endometrioid adenocarcinoma of different histological grade.
  • We have studied 104 postmenopausal women with diagnosis of endometrioid adenocarcinoma.
  • Histological grade of cancer was assessed by FIGO grading system.
  • Histological study by hematoxylin-eosin has showed grade 1 endometrioid carcinoma in 35 cases (33.7%, group I), grade 2 adenocarcinoma in 44 cases (42.3%, group II), and grade 3 adenocarcinoma in 25 cases (24%, group III).
  • Our results suggest that the loss of E-cadherin expression is associated with a higher histological grade of uterine endometrioid adenocarcinoma, depth of myometrial invasion, lymph node positivity, coexistence of obesity and vaginal bleeding.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Endometrioid / metabolism. Uterine Neoplasms / metabolism
  • [MeSH-minor] Female. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369055.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


66. Ronga AB, Najia SK, Sahasrabudhe N, Prescott R, Buruiana FE, Heazell A: Endometrioid adenocarcinoma presenting in a patient 18 years after hysterectomy: a potential hazard of unopposed oestrogen therapy. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma presenting in a patient 18 years after hysterectomy: a potential hazard of unopposed oestrogen therapy.
  • We present a case of endometrioid adenocarcinoma arising from extragonadal endometriosis 18 years after total abdominal hysterectomy with bilateral salpingo-oophorectomy.
  • Following resection, histopathology identified the mass as an endometrioid adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Dec;40(6):3065-73 [338141.001]
  • [Cites] Fertil Steril. 2008 Nov;90(5):1559-70 [18993168.001]
  • [Cites] Climacteric. 2006 Oct;9(5):325-35 [17000581.001]
  • [Cites] Surg Oncol. 2008 Dec;17(4):289-93 [18456491.001]
  • [Cites] Hum Reprod. 2007 Nov;22(11):3021-6 [17855408.001]
  • [Cites] Fertil Steril. 2007 Sep;88(3):588-93 [17320873.001]
  • (PMID = 21841948.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027906
  •  go-up   go-down


67. Valenzuela P, Ramos P, Redondo S, Cabrera Y, Alvarez I, Ruiz A: Endometrioid adenocarcinoma of the ovary and endometriosis. Eur J Obstet Gynecol Reprod Biol; 2007 Sep;134(1):83-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma of the ovary and endometriosis.
  • OBJECTIVE: We present a retrospective analysis of 22 cases of endometrioid ovarian carcinoma, reviewed to identify endometriosis and its malignant transformation.
  • STUDY DESIGN: Twenty-two patients with endometrioid ovarian cancer were included in the review.
  • The origin of the tumours was considered endometriosis-related when the presence of malignant changes in endometriosis glands leading to endometrioid carcinoma were found.
  • In the third, a pre-menopausal woman, ovarian endometriosis with only focal endometrioid carcinoma was observed.
  • The three of them had a clear-cell carcinoma component.
  • The presence of a clear-cell component was significantly greater in patients with endometriosis than in patients without endometriosis Each patient had a different clinical presentation: increase in abdominal perimeter, post-menopausal vaginal haemorrhage and hypermenorrhea.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Carcinoma, Endometrioid / etiology. Endometriosis / complications. Ovarian Neoplasms / etiology
  • [MeSH-minor] CA-125 Antigen / blood. Cell Transformation, Neoplastic. Female. Humans. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844279.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


68. Hanley KZ, Dustin SM, Stoler MH, Atkins KA: The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma. Int J Gynecol Pathol; 2010 Sep;29(5):445-51
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma.
  • Depth of myometrial invasion by endometrioid adenocarcinoma (EMAC) is one of the most important predictive factors of disease recurrence.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adenomyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736770.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T: Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res; 2005 Nov-Dec;25(6B):4101-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.
  • The current study aimed to evaluate whether the expression of MMP-2 is associated with survival in patients with endometrial endometrioid adenocarcinoma.
  • The MMP-2 immunoreactive protein was evaluated from endometrioid adenocarcinoma of the endometrium in 112 patients treated at Oulu University Hospital, Finland.
  • These data suggest that MMP-2 immunostaining negativity might be linked with a favourable prognosis in endometrial endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / enzymology. Endometrial Neoplasms / enzymology. Matrix Metalloproteinase 2 / biosynthesis
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309203.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


70. Metindir J, Dilek GB: The role of omentectomy during the surgical staging in patients with clinical stage I endometrioid adenocarcinoma. J Cancer Res Clin Oncol; 2008 Oct;134(10):1067-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of omentectomy during the surgical staging in patients with clinical stage I endometrioid adenocarcinoma.
  • OBJECTIVE: The aim of this study was to evaluate whether omentectomy should be a routine part of staging surgery in endometrioid adenocarcinoma.
  • METHODS: A retrospective study was performed on 65 patients who were primarily treated by total abdominal hysterectomy, salpingo-oophorectomy, bilateral pelvic and para-aortic lymphadenectomy, infracolic omentectomy and peritoneal cytology for clinical stage I endometrial carcinoma between January 2002 and December 2005.
  • Data on 65 patients who had been diagnosed with clinical stage I endometrial carcinoma were reviewed.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Genital Neoplasms, Female / pathology. Genital Neoplasms, Female / surgery. Omentum / pathology. Omentum / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Staging / methods. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386056.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


71. Jiang L, Malpica A, Deavers MT, Guo M, Villa LL, Nuovo G, Merino MJ, Silva EG: Endometrial endometrioid adenocarcinoma of the uterine corpus involving the cervix: some cases probably represent independent primaries. Int J Gynecol Pathol; 2010 Mar;29(2):146-56
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial endometrioid adenocarcinoma of the uterine corpus involving the cervix: some cases probably represent independent primaries.
  • The majority of endometrial endometrioid adenocarcinomas involving the cervix have tumor morphology that is similar in the endometrium and the endocervix.
  • There are, however, some cases in which the morphology of the tumor in the endocervix is different from the endometrial carcinoma, in which it is more invasive than the endometrial carcinoma, or in which invasion only occurs in the endocervix while there is no or only minimal myometrial invasion.
  • We selected 14 cases of endometrial endometrioid adenocarcinomas involving the cervix with complete pathology material available from the years between 1968 and 2004.
  • The immunohistochemical studies showed some differences between the endometrial and endocervical adenocarcinomas in 8 of the 12 cases, independent of differing or similar histologic features.
  • Clonality studies showed differences between the adenocarcinoma in the endometrium and the endocervix in 7 cases, including 5 cases with different histologic appearances; 2 cases had similar loss of heterozygosity patterns.
  • In conclusion, as suggested by clonality studies, coexisting endometrial and endocervical carcinomas with different histologic features are most likely independent neoplasms.
  • Endometrial and endocervical carcinomas that have similar appearances can represent either the same neoplasm or independent primaries.
  • IHC studies may not be helpful for synchronous endometrial and endocervical tumors, especially those of endometrioid type.
  • It is possible that IHC identifies cell differentiation, rather than site of origin.
  • [MeSH-major] Carcinoma, Endometrioid / virology. Endometrial Neoplasms / virology. Papillomaviridae / genetics. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] DNA, Viral / analysis. DNA, Viral / genetics. Female. Humans. Immunohistochemistry. In Situ Hybridization. RNA, Viral / analysis. RNA, Viral / genetics. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173500.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


72. Yamazawa K, Hirashiki K, Usui H, Mitsuhashi A, Matsui H, Sekiya S: Discordance between serum level and tissue immunohistochemical staining of CA125 in endometrioid adenocarcinoma of the uterine corpus. Int J Gynecol Pathol; 2005 Jul;24(3):254-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordance between serum level and tissue immunohistochemical staining of CA125 in endometrioid adenocarcinoma of the uterine corpus.
  • The records of 52 endometrioid adenocarcinomas diagnosed were reviewed.
  • [MeSH-major] Biomarkers, Tumor / metabolism. CA-125 Antigen / metabolism. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968201.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


73. Slater M, Cooper M, Murphy CR: Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma. Acta Histochem; 2006;108(1):13-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma.
  • In this retrospective and quantitated study on banked tissue we found that, compared to normal uterine epithelial cells, growth hormone (GH) is increased 3.4-fold in endometriosis and 3.8-fold in endometrial adenocarcinoma.
  • Similarly, interleukin-6 (IL-6) is increased 2.4-fold in endometriosis and 4.4-fold in endometrial adenocarcinoma.
  • Our results suggest that both IL-6 and GH may play a role in the progression of both endometriosis and endometrial carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Endometriosis / metabolism. Human Growth Hormone / metabolism. Interleukin-6 / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Peritoneal Diseases / metabolism. Up-Regulation

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564564.001).
  • [ISSN] 0065-1281
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-6; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


74. Pozharisskiĭ KM, Samsonova EA, Ten VP, Maksimova NA, Urmancheeva AF: [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value]. Arkh Patol; 2005 Mar-Apr;67(2):13-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value].
  • 76 endometrioid adenocarcinomas of the uterine body were studied.
  • Expression of the above markers is of essential value together with metastatic involvement of regional lymph nodes, stage of the disease and pathogenetic variant for determining prognosis of carcinoma aggressiveness and disease outcome.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ki-67 Antigen / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Steroid / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938112.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Steroid; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


75. Odashiro AN, Odashiro DN, Nguyen GK: Minimal deviation endometrioid adenocarcinoma of the cervix: report of three cases with exfoliative cytology. Diagn Cytopathol; 2006 Feb;34(2):119-23
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation endometrioid adenocarcinoma of the cervix: report of three cases with exfoliative cytology.
  • Three histologically confirmed minimal deviation endometrioid adenocarcinomas (MDEA) of the uterine cervix with cytologic evaluation by cervical scraping were reviewed.
  • The cytologic manifestations of those three cervical MDEAs overlapped, to some extents, with those of a cervical adenocarcinoma in situ and with those of a well-differentiated endometrial adenocarcinoma invading the cervix.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16511847.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Desrosiers L, Fadare O, Xiao ZF, Dresser K, Wang SA: Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium. Ann Diagn Pathol; 2008 Apr;12(2):112-7
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium.
  • This study was conducted to determine whether, in a pure population of patients with International Federation of Gynecology and Obstetrics stage I endometrioid endometrial (S1EE) carcinoma that is confined to the uterus and without lymph node metastases, the presence of lymphovascular space invasion (LVSI) is positively associated with vaginal relapses.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325471.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Hong DG, Chong GO, Seong WJ, Lee YS, Cho YL, Park JY, Chae JM, Park IS: A case of ovarian endometrioid adenocarcinoma with yolk sac tumor in a 35-year-old woman. Eur J Gynaecol Oncol; 2010;31(4):471-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with yolk sac tumor in a 35-year-old woman.
  • Ovarian yolk sac tumor (YST) is a malignant ovarian neoplasm differentiated from primordial germ cells that occur in young age, while endometrioid carcinoma (ECA) is a müllerian epithelial tumor that usually occurs in older patients.
  • We present a case of a simultaneous ECA and a YST component in a 35-year-old woman.
  • The parts of both ovaries that showed an endometrioid-like glandular pattern were positive for cytokeratin 7 and negative for AFP, but the YST component was negative for cytokeratin 7 and positive for AFP.
  • The patient failed to respond and succumbed to the disease after 12 months of follow-up.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882900.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


78. Mylonas I, Mayr D, Walzel H, Shabani N, Dian D, Kuhn C, Kunze S, Jeschke U, Friese K: Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis. Anticancer Res; 2007 Jul-Aug;27(4A):1975-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis.
  • BACKGROUND AND AIM: Altered mucin 1 (MUC1) secretion patterns have been implicated in several cancerous conditions including gastric, colorectal and breast carcinomas.
  • Therefore, the aims of this study were to determine the frequency and tissue distribution of MUC1, TF and gal-1 binding in endometrioid adenocarcinomas.
  • MATERIALS AND METHODS: Endometrial carcinomas diagnosed with only one histological tumor form (endometrioid adenocarcinomas) were obtained from 70 patients and classified according to the WHO grading system (G1 = 50; G2 = 12; G3 = 8).
  • RESULTS: MUC1, TF and gal-1 were observed in human endometrioid adenocarcinomas.
  • However TF showed a significant correlation with MUC1 (p = 0.019) in G1 and G2 endometrioid adeno-carcinomas, with no observed correlation in G3 tumors.
  • CONCLUSION: An immuno-histochemical expression of MUC1 and TF and gal-1 binding was demonstrated in human endometrioid adenocarcinomas.
  • Gal-1 binding was associated with lymphangiosis, which is thought to be a poor prognostic marker in endometrial adenocarcinomas.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / biosynthesis. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Galectin 1 / metabolism. Mucin-1 / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649808.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Galectin 1; 0 / Mucin-1; 3554-90-3 / Thomsen-Friedenreich antigen
  •  go-up   go-down


79. Arafa M, Kridelka F, Mathias V, Vanbellinghen JF, Renard I, Foidart JM, Boniver J, Delvenne P: High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology; 2008 Nov;53(5):525-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma.
  • AIMS: To identify a DNA methylation signature of endometrioid carcinoma of the endometrium (EEC) in the early stages of endometrial carcinogenesis.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Endometrial Neoplasms / genetics. Endometrium / metabolism. Promoter Regions, Genetic / genetics. Receptors, Retinoic Acid / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. DNA Methylation. Female. Gene Expression Regulation, Neoplastic. Humans. Microsatellite Instability. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783461.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RARB2 protein, human; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


80. Geisler JP, Buller E, Manahan KJ: Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary. Eur J Gynaecol Oncol; 2008;29(2):126-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary.
  • OBJECTIVE: The purpose of this study was to analyze estrogen receptor alpha and beta (ERalpha, ERbeta) expression in a stage and grade matched cohort of patients with serous and endometrioid adenocarcinoma of the ovary.
  • METHODS: Forty-two patients from 1991 to the present were found to have the diagnosis of endometrioid adenocarcinoma of the ovary and have tissue available for analysis.
  • These were stage and grade matched with ten patients having serous adenocarcinoma of the ovary during the same time period.
  • RESULTS: ERalpha expression was present in ten of ten endometrioid adenocarcinomas but in only five of ten serous carcinomas (chi2, p = 0.01).
  • ERbeta expression was present in six of ten endometrioid adenocarcinomas and in four of ten serous caricinomas (chi2, p = 0.65).
  • CONCLUSIONS: ERalpha expression, but not ERbeta expression, is significantly more common in endometrioid than serous adenocarcinomas of the ovary when controlled for stage and grade.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Estrogen Receptor alpha / genetics. Estrogen Receptor beta / genetics. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Case-Control Studies. CpG Islands. DNA Methylation. Female. Humans. Neoplasm Staging. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459544.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA 79445-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / RNA, Messenger
  •  go-up   go-down


81. Salerno MG, Masciullo V, Naldini A, Zannoni GF, Vellone V, Scambia G: Endometrioid adenocarcinoma with squamous differentiation arising from ureteral endometriosis in a patient with no history of gonadal endometriosis. Gynecol Oncol; 2005 Dec;99(3):749-52
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma with squamous differentiation arising from ureteral endometriosis in a patient with no history of gonadal endometriosis.
  • CASE: An endometrioid carcinoma with squamous differentiation arising from periureteral endometriosis presented as a pelvic mass encasing the right ureter.
  • CONCLUSION: This is the second case of a malignancy arising in endometriosis presenting as an obstructive ureteral mass and the first case of a patient with this condition whose endometriosis is not consistent with a gonadal origin.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Squamous Cell / pathology. Endometriosis / pathology. Ureteral Neoplasms / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic / pathology. Female. Humans. Hysterectomy. Middle Aged. Ureter / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226301.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Dilek S, Dede M, Gezginç K, Yenen MC, Göktolga U, Ulutin HC, Deveci MS, Erdemoglu E, Aydogdu T: Does the localisation of tumour at stage I endometrial endometrioid adenocarcinoma have an impact on invasion of the tumour and individualisation of the surgical procedure? Eur J Gynaecol Oncol; 2008;29(2):138-40
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the localisation of tumour at stage I endometrial endometrioid adenocarcinoma have an impact on invasion of the tumour and individualisation of the surgical procedure?
  • MATERIAL METHOD: 106 clinically surgically stage I endometrial endometrioid carcinoma cases treated multi-institutionally at Gulhane Military Medical Academy (GATA) and Dr.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Hysterectomy / methods. Lymph Node Excision / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459547.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


83. Koizumi T, Nakaya N, Okamura C, Sato Y, Shimazu T, Nagase S, Niikura H, Kuriyama S, Tase T, Ito K, Tsubono Y, Okamura K, Yaegashi N, Tsuji I: Case-control study of coffee consumption and the risk of endometrial endometrioid adenocarcinoma. Eur J Cancer Prev; 2008 Aug;17(4):358-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-control study of coffee consumption and the risk of endometrial endometrioid adenocarcinoma.
  • This study examined the association between coffee consumption and the risk of endometrial endometrioid adenocarcinoma (EEA) in Japan by a case-control design.
  • The controls, selected from the participants of a cancer-screening program, were 214 women, with two controls selected for each case (matched for age and for area of residence).
  • A self-administered questionnaire containing questions to determine dietary and beverage consumption, as well as reproductive history, was distributed to the cases and controls.
  • [MeSH-major] Carcinoma, Endometrioid / epidemiology. Carcinoma, Endometrioid / prevention & control. Coffee / adverse effects. Endometrial Neoplasms / epidemiology. Endometrial Neoplasms / prevention & control
  • [MeSH-minor] Adult. Age Distribution. Aged. Case-Control Studies. Chi-Square Distribution. Drinking. Female. Follow-Up Studies. Humans. Incidence. Japan / epidemiology. Middle Aged. Multivariate Analysis. Odds Ratio. Postmenopause. Premenopause. Probability. Reference Values. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18562962.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coffee
  •  go-up   go-down


84. Uzan C, Darai E, Valent A, Graesslin O, Cortez A, Rouzier R, Vielh P: Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. Virchows Arch; 2009 May;454(5):525-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma.
  • A role for the EGF system, in particular HER1 and 2, in growth of the endometrium has been suggested but HER1 and 2 have not been studied in all locations of endometriosis and in ovarian endometrioid adenocarcinoma (OEC) which is a rare form of malignant transformation of endometriosis.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometriosis / metabolism. Intestinal Diseases / metabolism. Ovarian Neoplasms / metabolism. Peritoneal Diseases / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Aneuploidy. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Colonic Diseases / metabolism. Colonic Diseases / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. In Situ Hybridization, Fluorescence. Rectal Diseases / metabolism. Rectal Diseases / pathology. Stromal Cells / metabolism. Stromal Cells / pathology


85. Kamata Y, Watanabe J, Nishimura Y, Arai T, Kawaguchi M, Hattori M, Obokata A, Kuramoto H: High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma. J Cancer Res Clin Oncol; 2005 Sep;131(9):591-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma.
  • This study aimed to investigate the correlation of skp2 expression with the expression of p27 and other cell cycle regulators, and clinicopathological parameters in endometrial endometrioid adenocarcinoma.
  • METHODS: Tissue samples of 136 endometrioid adenocarcinomas, in addition to 20 endometrial hyperplasias and 20 normal endometria, were immunohistochemically stained for skp2.
  • RESULTS: Skp2 staining was localized in the nuclei of the glandular cells of the proliferative phase endometrium, and endometrial hyperplasia and carcinoma cells.
  • The LI of skp2 in endometrial carcinoma was significantly correlated with that of p27, Ki-67, cdk2, cyclin A, cyclin D1, cyclin E, p53 and PTEN.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. S-Phase Kinase-Associated Proteins / biosynthesis
  • [MeSH-minor] Cell Cycle Proteins / biosynthesis. Female. Humans. Immunohistochemistry. Prognosis. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080017.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / S-Phase Kinase-Associated Proteins
  •  go-up   go-down


86. Liu WK, Jiang XY, Ren JK, Zhang ZX: Expression pattern of the ASPP family members in endometrial endometrioid adenocarcinoma. Onkologie; 2010;33(10):500-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression pattern of the ASPP family members in endometrial endometrioid adenocarcinoma.
  • MATERIAL AND METHODS: The expression pattern of the ASPP family consisting of ASPP1, ASPP2, and iASPP was examined by immunohistochemistry in 45 formalin-fixed and paraffin-embedded endometrial endometrioid adenocarcinoma (EEA) specimens and 26 normal endometrial tissue (NET) samples.
  • CONCLUSIONS: It is a novel finding that the expression pattern of the ASPP family members has respective pathological and clinical implications in EEA, and iASPP might be a candidate target for EEA therapy.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma / metabolism. Apoptosis Regulatory Proteins / metabolism. Biomarkers, Tumor / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20926896.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / PPP1R13B protein, human; 0 / PPP1R13L protein, human; 0 / Repressor Proteins; 0 / TP53BP2 protein, human
  •  go-up   go-down


87. Al-Talib A, Gilbert L, Arseneau J: Endometrioid adenocarcinoma 13 years after total abdominal hysterectomy and bilateral salpingo-oophorectomy. Saudi Med J; 2008 Jul;29(7):1044-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma 13 years after total abdominal hysterectomy and bilateral salpingo-oophorectomy.
  • We describe a case of a 68-year-old woman who underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometriosis.
  • Pleural effusion was tapped and biopsy from the peritoneal mass showed metastatic adenocarcinoma; immunohistochemistry findings favored endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / etiology. Endometriosis / pathology. Peritoneal Neoplasms / etiology
  • [MeSH-minor] Aged. Estrogen Replacement Therapy. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Ovariectomy. Time Factors

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18626539.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


88. Steinbakk A, Malpica A, Slewa A, Gudlaugsson E, Janssen EA, Arends M, Kruse AJ, Yinhua Y, Feng W, Baak JP: High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases. Anal Cell Pathol (Amst); 2010;33(5):245-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases.
  • OBJECTIVES: to analyze the prognostic value of microsatellite instability (MSI) in a population-based study of FIGO stage 1-4 endometrial endometrioid adenocarcinomas.
  • CONCLUSIONS: MSI-H status assessed by pentaplex polymerase chain reaction is an indicator of poor prognosis in FIGO 1, but not in FIGO 2-4 endometrial endometrioid adenocarcinomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Endometrioid / genetics. Microsatellite Instability
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Cell Oncol (Dordr). 2011 Oct;34(5):457-65 [21547578.001]
  • (PMID = 21079294.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC4605578
  •  go-up   go-down


89. Kakuta Y, Nakaya N, Nagase S, Fujita M, Koizumi T, Okamura C, Niikura H, Ohmori K, Kuriyama S, Tase T, Ito K, Minami Y, Yaegashi N, Tsuji I: Case-control study of green tea consumption and the risk of endometrial endometrioid adenocarcinoma. Cancer Causes Control; 2009 Jul;20(5):617-24
Hazardous Substances Data Bank. Green tea .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-control study of green tea consumption and the risk of endometrial endometrioid adenocarcinoma.
  • OBJECTIVE: To investigate the association between green tea consumption and the risk of endometrial cancer restricted to endometrial endometrioid adenocarcinoma (EEA) using a case-control design in Japan.
  • The subjects completed a questionnaire regarding health-related lifestyle and reproductive history, and a food frequency questionnaire.
  • [MeSH-major] Carcinoma, Endometrioid / epidemiology. Endometrial Neoplasms / epidemiology. Tea
  • [MeSH-minor] Case-Control Studies. Female. Humans. Risk Factors. Surveys and Questionnaires

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19067194.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tea
  •  go-up   go-down


90. Nofech-Mozes S, Ghorab Z, Ismiil N, Ackerman I, Thomas G, Barbera L, Covens A, Khalifa MA: Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases. Am J Clin Pathol; 2008 Jan;129(1):110-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases.
  • We reviewed 827 consecutive cases of pure endometrial endometrioid adenocarcinoma (EEA) treated by hysterectomy to update the distribution of pathologic features.
  • Tumor grade (reported in a 2-tiered system), depth of myometrial invasion, presence of cervical involvement, lymphovascular invasion (LVI), and evidence of extrauterine disease were recorded.The median age at diagnosis was 62 years (range, 30-94 years).
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Nodes / pathology. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Ovarian Neoplasms / secondary. Ovary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089496.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Flemming R, Sathiyathasan S, Jackson A: Endometrioid adenocarcinoma after insertion of a levonorgestrel-releasing intrauterine system. J Minim Invasive Gynecol; 2008 Nov-Dec;15(6):771-3
Hazardous Substances Data Bank. LEVONORGESTREL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma after insertion of a levonorgestrel-releasing intrauterine system.
  • The levonorgestrel-releasing intrauterine system (IUS) is now widely used and recommended as a reliable contraceptive and treatment for menorrhagia.
  • Endometrial biopsy specimen confirmed well-differentiated endometrioid adenocarcinoma.
  • This case raises the question of the safety of levonorgestrel-releasing IUS for the prevention and treatment of endometrial hyperplasia and carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Contraceptive Agents, Female / therapeutic use. Endometrial Neoplasms / surgery. Intrauterine Devices / adverse effects. Levonorgestrel / therapeutic use. Menorrhagia / prevention & control
  • [MeSH-minor] Adult. Female. Humans. Hysterectomy. Magnetic Resonance Imaging. Ovariectomy. Salpingostomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971148.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 5W7SIA7YZW / Levonorgestrel
  •  go-up   go-down


92. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR: Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell; 2007 Apr;11(4):321-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
  • One histologic subtype of ovarian carcinoma, ovarian endometrioid adenocarcinoma (OEA), frequently harbors mutations that constitutively activate Wnt/beta-catenin-dependent signaling.
  • Deregulation of these two pathways in the murine ovarian surface epithelium by conditional inactivation of the Pten and Apc tumor suppressor genes results in the formation of adenocarcinomas morphologically similar to human OEAs with 100% penetrance, short latency, and rapid progression to metastatic disease in upwards of 75% of mice.
  • [MeSH-major] Disease Models, Animal. Ovarian Neoplasms / genetics. PTEN Phosphohydrolase / genetics. Phosphatidylinositol 3-Kinases / genetics. Signal Transduction. Wnt1 Protein / genetics. beta Catenin / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenomatous Polyposis Coli Protein / genetics. Adenomatous Polyposis Coli Protein / physiology. Animals. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Epithelium / metabolism. Epithelium / pathology. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Mice. Mutation. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Ovary / metabolism. Ovary / pathology. Survival Rate. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


93. Işin Doğan Ekici A, Küçükali T, Coşkun Salman M, Ayhan A: Triple simultaneous primary gynecological malignancies in a 56-year-old patient. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1947-50
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, the clinical and pathologic findings of a 56-year-old female patient with synchronous triple primary gynecological cancers including well-differentiated ovarian mucinous cystadenocarcinoma, well-differentiated endometrial endometrioid adenocarcinoma, and uterine leiomyosarcoma were presented.
  • Synchronous primary, well-differentiated endometrial endometrioid adenocarcinoma and leiomyosarcoma of uterus without any ovarian neoplasm has only been once described in the English literature.
  • To our knowledge, the presented patient is the first case in aspect of accompanying ovarian mucinous adenocarcinoma to endometrial endometrioid adenocarcinoma and leiomyosarcoma of uterus.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / pathology. Leiomyosarcoma / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Endometrium / pathology. Female. Humans. Middle Aged. Myometrium / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009998.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Nofech-Mozes S, Ackerman I, Ghorab Z, Ismiil N, Thomas G, Covens A, Khalifa MA: Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma. Am J Clin Pathol; 2008 Jun;129(6):912-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma.
  • To evaluate the value of lymphovascular invasion (LVI) in endometrial endometrioid adenocarcinoma (EEA) as a predictor for distant recurrence, we analyzed the histopathologic features of 513 consecutive cases of nonsurgically staged EEA limited to the uterus.
  • LVI was identified in 116 cases (22.6%) cases and was the only adverse histopathologic finding in 23 cases; 5 (22%) of the 23 recurred.
  • Studies to examine the role of adjuvant systemic therapy in patients with early-stage disease should be considered.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Cervix Uteri / pathology. Female. Humans. Hysterectomy. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480008.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, Frost AR, LoBuglio AF, Grizzle WE, Johnson MR: Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn; 2006 Feb;8(1):76-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma.
  • However, these pathways remain unexplored in ovarian endometrioid adenocarcinoma (OEA).

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Dec 20;18(55):7844-51 [10630637.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):1005-9 [10984056.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8247-55 [11719457.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2741-9 [12072409.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2215-20 [12174906.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] J Cell Sci. 2002 Dec 1;115(Pt 23):4393-7 [12414986.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2435-45 [12460789.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Cancer. 2003 May 15;97(10 Suppl):2648-59 [12733130.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Development. 2003 Nov;130(22):5297-305 [14530294.001]
  • [Cites] Lancet. 1989 Jun 17;1(8651):1391 [2567404.001]
  • [Cites] J Clin Pathol. 1990 Jun;43(6):499-504 [1696290.001]
  • [Cites] Biotechniques. 1991 Sep;11(3):304, 306, 308 [1718327.001]
  • [Cites] Biotechniques. 1993 Mar;14(3):448-53 [7681300.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 12):40-7 [8941409.001]
  • [Cites] Methods Mol Biol. 1998;86:23-6 [9664448.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Mol Carcinog. 1999 Jun;25(2):86-91 [10365909.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):224-9 [14710233.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):559-67 [14766248.001]
  • [Cites] Chin Med Sci J. 2004 Mar;19(1):25-30 [15104221.001]
  • [Cites] Oncology. 2004;66(4):310-5 [15218299.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Anal Biochem. 2000 Feb 15;278(2):175-84 [10660460.001]
  • (PMID = 16436637.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA086359-06; United States / NCI NIH HHS / CA / P20 CA101955; United States / NCI NIH HHS / CA / CA101955-01; United States / NCI NIH HHS / CA / P50 CA101955; United States / NCI NIH HHS / CA / U24 CA086359
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fixatives; 0 / Hedgehog Proteins; 0 / Trans-Activators; 0 / Wnt Proteins; 1HG84L3525 / Formaldehyde
  • [Other-IDs] NLM/ PMC1867577
  •  go-up   go-down


96. Kazandi M, Zeybek B, Terek MC, Zekioglu O, Ozdemir N, Oztekin K: Grade 2 endometrioid adenocarcinoma arising from adenomyosis of the uterus: report of a case. Eur J Gynaecol Oncol; 2010;31(6):719-21
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grade 2 endometrioid adenocarcinoma arising from adenomyosis of the uterus: report of a case.
  • Adenocarcinomas arising within adenomyosis need to be distinguished from endometrial carcinomas which arise from the eutopic endometrium, then extend into preexisting adenomyosis of the uterine wall.
  • We report a case of grade 2 endometrioid adenocarcinoma arising from an adenomyotic focus in the uterus.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adenomyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319528.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


97. Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, Fischer AH: Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol; 2007 Dec;20(12):1263-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
  • To investigate the diagnostic and clinicopathologic significance of this protein in endometrial carcinomas, we evaluated immunohistochemical expression of IMP3 in the two most common forms of endometrial malignancies, endometrioid adenocarcinoma and serous carcinoma.
  • We selected 167 endometrial adenocarcinoma cases including 122 cases of endometrioid adenocarcinoma and 45 cases of serous carcinoma.
  • Positive immunohistochemical stain for IMP3 was identified in all serous carcinoma cases, among which, 39 (86%) and 3 (7%) cases showed IMP3 immunoreactivity in >50%, and 21-50, or 6-20% of tumor cells, respectively.
  • Immunohistochemical reaction intensity for IMP3 was identified to be strong in 38 (84%) and intermediate in 7 (16%) cases of serous carcinoma.
  • Fifty-four (44%) cases of endometrioid adenocarcinoma were negative for IMP3.
  • Thirty (25%), 20 (16%), 10 (8%), and 8 (7%) cases of endometrioid adenocarcinoma demonstrated positive immunoreactivity for IMP3 in 1-5, 6-20, 21-50, and >50% of the tumor cells.
  • Strong IMP3-staining intensity was noted in 34 (28%), intermediate in 26 (21%), and weak in 8 (7%) cases of endometrioid adenocarcinoma.
  • To compare p53 with IMP3 expressions, we found that 35 (78%) of the serous carcinoma cases showed strong p53 immunohistochemical activity in >50% of the tumor cell nuclei.
  • In contrast, 11 of 112 (10%) endometrioid adenocarcinoma cases demonstrated strong p53 positivity in >50% of the tumor cell nuclei.
  • In conclusion, our findings demonstrate significant expression of IMP3 in serous carcinoma as compared to endometrioid adenocarcinoma (P<0.0001).
  • Expression of IMP3 and p53 may be helpful biomarkers in the distinction of endometrial serous carcinoma from endometrioid adenocarcinoma.
  • In addition, expression of IMP3 in endometrioid adenocarcinoma correlates with higher nuclear and architecture grades of the tumor (P=0.0000 and P=0.0002, respectively).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / biosynthesis. Diagnosis, Differential. Female. Gene Expression. Humans. Immunohistochemistry. Middle Aged. Tumor Suppressor Protein p53 / biosynthesis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885673.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; 0 / oncofetal antigens
  •  go-up   go-down


98. Pradhan M, Abeler VM, Danielsen HE, Tropé CG, Risberg BA: Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol; 2006 Sep;19(9):1227-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas.
  • Image cytometric DNA ploidy analysis of endometrial carcinomas was performed to determine whether ploidy status and ploidy-related parameters like DNA index, percentage of cells exceeding 5c and 9c, correlate with histologic subtype.
  • This is a prospective study of 391 patients with stage I endometrial carcinoma which included 331 (85%) endometrioid adenocarcinoma, 22 (6%) serous adenocarcinoma, 7 (2%) clear cell adenocarcinoma, 2 (0.5%) small cell carcinoma, 1 (0.3%) undifferentiated carcinoma, and 28 (7%) unclassifiable adenocarcinoma.
  • Twenty-five percent of endometrioid adenocarcinomas were non-diploid.
  • In contrast, all clear cell adenocarcinomas and 21/22 (95%) of serous adenocarcinomas were non-diploid.
  • Hyperdiploidy (25 cases) was found only in endometrioid adenocarcinomas.
  • Mean DNA index of the stemline in serous adenocarcinoma (1.72) and clear cell adenocarcinoma (1.81) was higher than in endometrioid adenocarcinoma (1.1).
  • The difference in ploidy-related parameters between endometrioid adenocarcinoma and serous adenocarcinoma was highly significant (P<0.001).
  • In addition, Grade 3 endometrioid adenocarcinoma showed significant difference in all ploidy-related parameters compared with grade 1 and grade 2 tumors (P<0.001).
  • Our results show that DNA ploidy-related parameters may be valuable in subtyping histologically difficult cases of endometrial carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. DNA, Neoplasm / analysis. Endometrial Neoplasms / genetics. Image Cytometry / methods
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Cell Count. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 26 May 2006.
  • (PMID = 16729014.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


99. Tamura T, Jobo T, Watanabe J, Kanai T, Kuramoto H: Neuroendocrine features in poorly differentiated endometrioid adenocarcinomas of the endometrium. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):821-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine features in poorly differentiated endometrioid adenocarcinomas of the endometrium.
  • This study aimed to clarify neuroendocrine features (NEF) in poorly differentiated (G3) endometrioid adenocarcinoma of the endometrium and to evaluate its prognostic significance.
  • Forty cases with G3 carcinoma were investigated for NEF immunohistochemically.
  • A patient with diffusely positive staining for both chromogranin A and synaptophysin was diagnosed with neuroendocrine carcinoma.
  • NEF was detected immunohistochemically in approximately 63% of the G3 carcinomas, and these patients had a poor prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Endometrial Neoplasms / pathology. Neurosecretory Systems / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD57 / metabolism. Cell Differentiation. Chromogranin A. Chromogranins / metabolism. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate. Synaptophysin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681768.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Chromogranins; 0 / Synaptophysin
  •  go-up   go-down


100. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, Pollak MN, Anderson G, Howard BV, Strickler HD: A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev; 2008 Apr;17(4):921-9
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cox models were used to estimate associations with endometrial cancer, particularly endometrioid adenocarcinomas, the main histologic type (n = 205).
  • Our data showed that insulin levels were positively associated with endometrioid adenocarcinoma [hazard ratio contrasting highest versus lowest quartile (HR(q4-q1)), 2.33; 95% confidence interval (95% CI), 1.13-4.82] among women not using hormone therapy after adjustment for age and estradiol.
  • Free IGF-I was inversely associated with endometrioid adenocarcinoma (HR(q4-q1), 0.53; 95% CI, 0.31-0.90) after adjustment for age, hormone therapy use, and estradiol.
  • Both of these associations were stronger among overweight/obese women, especially the association between insulin and endometrioid adenocarcinoma (HR(q4-q1), 4.30; 95% CI, 1.62-11.43).
  • These data indicate that hyperinsulinemia may represent a risk factor for endometrioid adenocarcinoma that is independent of estradiol.
  • Free IGF-I levels were inversely associated with endometrioid adenocarcinoma, consistent with prior cross-sectional data.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):649-54 [8547832.001]
  • [Cites] Endocrinology. 1995 Jun;136(6):2531-7 [7750475.001]
  • [Cites] Mol Hum Reprod. 1997 Jan;3(1):21-6 [9239705.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2497-502 [9253324.001]
  • [Cites] Control Clin Trials. 1998 Feb;19(1):61-109 [9492970.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jul;179(1):6-12 [9704758.001]
  • [Cites] Epidemiology. 1999 Jan;10(1):76-9 [9888284.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):188-93 [9935198.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Maturitas. 2005 Jun 16;51(2):187-98 [15917160.001]
  • [Cites] Horm Res. 2005;64(1):9-15 [16088202.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):972-8 [16702379.001]
  • [Cites] Growth Horm IGF Res. 2006 Apr;16(2):86-92 [16530441.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):255-63 [17062769.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2656-64 [17285578.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):329-37 [18172327.001]
  • [Cites] Diabetes Res Clin Pract. 2000 Mar;47(3):177-84 [10741566.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Sep;24(9):1085-92 [11033975.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):421-30 [11169969.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):736-9 [11267989.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1361-8 [12433712.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531-43 [12496040.001]
  • [Cites] Oncology. 2003;64(4):341-5 [12759530.001]
  • [Cites] Ann Epidemiol. 2003 Oct;13(9 Suppl):S107-21 [14575943.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1697-704 [14583772.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):262-8 [14639613.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):607-12 [15066926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):748-52 [15159305.001]
  • [Cites] Growth Horm IGF Res. 2004 Oct;14(5):337-75 [15336229.001]
  • [Cites] Oncology. 2004;67(1):54-9 [15459496.001]
  • [Cites] Crit Rev Clin Lab Sci. 1984;19(4):297-352 [6373142.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Endocr Rev. 1990 Aug;11(3):443-53 [2226350.001]
  • [Cites] Mol Endocrinol. 1987 Jul;1(7):445-50 [2484720.001]
  • [Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Dec;79(6):1723-34 [7527408.001]
  • [Cites] J Biol Chem. 1997 Jul 25;272(30):18650-5 [9228034.001]
  • (PMID = 18398032.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093881-01; United States / NCI NIH HHS / CA / R01 CA093881; United States / NCI NIH HHS / CA / R01 CA 93881-01; United States / NCI NIH HHS / CA / R01 CA093881-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Insulin-Like Growth Factor Binding Protein 1; 0 / Insulin-Like Growth Factor Binding Protein 3; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ NIHMS278460; NLM/ PMC3090086
  •  go-up   go-down






Advertisement